

Supplementary Information

Design, synthesis and *in vitro* evaluation of the hybrids of oxindolylidene and imidazothiazolotriazine as efficient antiproliferative agents

Alexei N. Izmet's'ev,^a Lada V. Anikina,^b Igor E. Zanin,^c Natalya G. Kolotyrkina,^a Ekaterina S. Izmalkova,^a Angelina N. Kravchenko^a and Galina A. Gazieva^{*a}

^a N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Pros., Moscow 119991, Russian Federation


^b Institute of Physiologically Active Compounds, Russian Academy of Sciences, 1 Severnyi Proezd, Chernogolovka 142432, Russian Federation

^c Voronezh State University, Universitetskaya Pl., 1, Voronezh 394018, Russian Federation


Corresponding author e-mail: gaz@ioc.ac.ru (Galina A. Gazieva).

1. Anticancer Screening Data of 60 Cancer Cell Lines of 1a-w and 5a-z	S2
2. Anticancer Screening Data of 60 Cancer Cell Lines of <i>Taxol</i> , <i>Doxorubicin</i> , <i>Camptothecin</i>	S10
3. Five dose testing results of compounds 5d-s	S11
4. Spectra ¹ H and ¹³ C NMR of 4c-t	S43
5. Spectra ¹ H and ¹³ C NMR of 1b and 1h-w	S79
6. Spectra ¹ H and ¹³ C NMR of 5e , 5h and 5j-z	S113
7. Spectra ¹ H and ¹³ C NMR of 7 and 8	S151
8. Space groups, unit cell parameters and characteristics of the investigated verification phases of compounds 1f-h , 1j , 1k , 1n , 1p , 1r , 1u-w , 5b , 5e , 5f , 5h , 5k , 5p , 5r and 5x-z	S155
9. Powder diffraction pattern for compounds 1j , 1k , 1r , 1u , 5b and 5e	S156


Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 $\mu\text{mol/L}$ Concentration




Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 μmol/L Concentration




Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 μmol/L Concentration




Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 μmol/L Concentration




Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 μmol/L Concentration




Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 $\mu\text{mol/L}$ Concentration




Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 $\mu\text{mol/L}$ Concentration



Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 µmol/L Concentration



Anticancer Screening Data of 60 Cancer Cell Lines Assay at 10 μmol/L Concentration



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 799674 / 1

Experiment ID : 1708NS59

Test Type : 08

Report Date : September 27, 2017


Test Date : August 28, 2017

QNS :










COMI : IA41

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Log10 Concentration												GI50	TGI	LC50
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.557	2.790	2.667	2.541	0.737	0.669	0.669	94	89	8	5	5	3.03E-7	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.752	2.648	2.509	2.473	0.574	0.553	0.531	93	91	-24	-26	-29	2.27E-7	6.21E-7	> 1.00E-4
K-562	0.143	1.102	1.085	1.010	0.278	0.248	0.215	98	90	14	11	8	3.38E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.761	2.970	2.967	2.829	1.081	0.900	0.904	100	94	14	6	6	3.56E-7	> 1.00E-4	> 1.00E-4
RPMI-8226	0.718	2.469	2.413	2.308	1.020	0.845	0.844	97	91	17	7	7	3.59E-7	> 1.00E-4	> 1.00E-4
SR	0.230	1.037	1.044	1.005	0.327	0.296	0.259	101	96	12	8	4	3.53E-7	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.289	1.350	1.295	1.236	0.453	0.376	0.364	95	89	15	8	7	3.40E-7	> 1.00E-4	> 1.00E-4
EKVX	0.609	1.712	1.696	1.532	1.056	0.863	0.848	99	84	41	23	22	6.03E-7	> 1.00E-4	> 1.00E-4
HOP-62	0.906	2.177	2.098	1.992	1.189	1.123	0.510	94	85	22	17	-44	3.64E-7	1.91E-5	> 1.00E-4
HOP-92	1.222	1.768	1.669	1.597	1.453	1.033	0.920	82	69	42	-16	-25	5.12E-7	5.39E-6	> 1.00E-4
NCI-H226	0.708	1.358	1.343	1.277	0.900	0.812	0.681	98	87	30	16	-4	4.43E-7	6.38E-5	> 1.00E-4
NCI-H23	0.524	1.941	1.900	1.810	0.879	0.718	0.472	97	91	25	14	-10	4.17E-7	3.78E-5	> 1.00E-4
NCI-H322M	0.835	2.027	1.971	1.926	1.407	1.294	1.320	95	92	48	38	41	8.97E-7	> 1.00E-4	> 1.00E-4
NCI-H460	0.206	2.216	2.318	2.164	0.371	0.257	0.295	105	97	8	3	4	3.40E-7	> 1.00E-4	> 1.00E-4
NCI-H522	0.865	2.274	2.086	1.979	1.219	0.734	0.923	87	79	25	-15	4	3.46E-7	.	> 1.00E-4
Colon Cancer															
COLO 205	0.424	1.526	1.491	1.485	0.446	0.266	0.262	97	96	2	-37	-38	3.09E-7	1.12E-6	> 1.00E-4
HCC-2998	1.608	3.402	3.424	3.435	1.834	1.492	1.516	101	102	13	-7	-6	3.81E-7	4.31E-6	> 1.00E-4
HCT-116	0.216	1.984	1.903	1.883	0.377	0.169	0.289	95	94	9	-22	4	3.31E-7	.	> 1.00E-4
HCT-15	0.247	1.721	1.786	1.633	0.349	0.277	0.257	104	94	7	2	1	3.20E-7	> 1.00E-4	> 1.00E-4
HT29	0.245	1.623	1.550	1.624	0.323	0.283	0.288	95	100	6	3	3	3.39E-7	> 1.00E-4	> 1.00E-4
KM12	0.457	2.450	2.501	2.273	0.849	0.656	0.741	103	91	20	10	14	3.76E-7	> 1.00E-4	> 1.00E-4
SW-620	0.197	1.696	1.629	1.535	0.535	0.544	0.528	96	89	23	23	22	3.88E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.517	1.860	1.838	1.668	1.137	0.808	0.561	98	86	46	22	3	7.98E-7	> 1.00E-4	> 1.00E-4
SF-295	0.796	2.730	2.551	2.370	0.634	0.564	0.177	91	81	-20	-29	-78	2.03E-7	6.30E-7	2.68E-5
SF-539	0.699	2.339	2.302	2.162	0.612	0.523	0.180	98	89	-12	-25	-74	2.43E-7	7.54E-7	3.21E-5
SNB-19	0.462	1.631	1.616	1.565	0.726	0.611	0.465	99	94	23	13	.	4.15E-7	> 1.00E-4	> 1.00E-4
SNB-75	0.924	2.205	2.131	1.832	1.195	1.201	0.495	94	71	21	22	-46	2.63E-7	2.08E-5	> 1.00E-4
U251	0.284	1.229	1.188	1.172	0.414	0.372	0.260	96	94	14	9	-8	3.53E-7	3.33E-5	> 1.00E-4
Melanoma															
LOX IMVI	0.279	2.041	2.029	1.840	0.793	0.487	0.434	99	89	29	12	9	4.46E-7	> 1.00E-4	> 1.00E-4
MALME-3M	0.548	1.293	1.309	1.212	0.963	0.783	0.721	102	89	56	32	23	1.71E-6	> 1.00E-4	> 1.00E-4
M14	0.450	1.607	1.593	1.471	0.414	0.458	0.333	99	88	-8	1	-26	2.49E-7	.	> 1.00E-4
MDA-MB-435	0.336	1.946	1.897	1.592	0.201	0.192	0.140	97	78	-40	-43	-58	1.73E-7	4.57E-7	2.83E-5
SK-MEL-2	1.067	2.451	2.399	2.462	1.526	1.287	0.805	96	101	33	16	-25	5.64E-7	2.47E-5	> 1.00E-4
SK-MEL-28	0.530	1.755	1.777	1.632	1.135	0.923	0.691	102	90	49	32	13	9.67E-7	> 1.00E-4	> 1.00E-4
SK-MEL-5	0.631	2.045	1.988	1.849	0.842	0.368	0.365	96	86	15	-42	-42	3.22E-7	1.83E-6	> 1.00E-4
UACC-257	1.250	2.234	2.094	2.057	1.789	1.779	1.539	86	82	55	54	29	1.42E-5	> 1.00E-4	> 1.00E-4
UACC-62	1.015	2.828	2.727	2.640	1.645	1.431	1.033	94	90	35	23	1	5.27E-7	> 1.00E-4	> 1.00E-4
Ovarian Cancer															
IGROV1	0.586	2.230	2.283	2.123	1.295	0.864	0.777	103	93	43	17	12	7.29E-7	> 1.00E-4	> 1.00E-4
OVCAR-3	0.461	1.610	1.670	1.646	0.423	0.333	0.300	105	103	-8	-28	-35	3.00E-7	8.42E-7	> 1.00E-4
OVCAR-4	0.685	1.465	1.524	1.361	1.116	0.827	0.930	108	87	55	18	31	1.38E-6	> 1.00E-4	> 1.00E-4
OVCAR-5	0.470	1.393	1.352	1.245	0.909	0.757	0.659	95	84	47	31	20	8.54E-7	> 1.00E-4	> 1.00E-4
OVCAR-8	0.381	1.446	1.450	1.379	0.525	0.406	0.371	100	94	14	2	-3	3.51E-7	2.85E-5	> 1.00E-4
NCI/ADR-RES	0.416	1.392	1.377	1.366	0.378	0.394	0.286	98	97	-9	-5	-31	2.78E-7	8.21E-7	> 1.00E-4
SK-OV-3	0.812	1.616	1.619	1.539	1.002	0.835	0.558	100	90	24	3	-31	4.03E-7	1.21E-5	> 1.00E-4
Renal Cancer															
786-0	0.597	2.482	2.390	2.284	1.532	0.633	0.367	95	89	50	2	-39	9.77E-7	1.11E-5	> 1.00E-4
A498	1.435	2.349	2.247	2.148	1.360	1.309	0.932	89	78	-5	-9	-35	2.17E-7	8.65E-7	> 1.00E-4
ACHN	0.282	1.197	1.197	1.128	0.522	0.363	0.208	100	92	26	9	-26	4.38E-7	1.78E-5	> 1.00E-4
CAKI-1	0.410	2.246	2.128	1.879	0.922	0.773	0.319	94	80	28	20	-22	3.76E-7	2.96E-5	> 1.00E-4
RXF 393	0.758	1.368	1.366	1.368	0.715	0.788	0.271	100	100	-6	5	-64	2.97E-7	.	6.21E-5
SN12C	0.630	2.151	2.027	1.994	1.279	0.886	0.936	92	90	43	17	20	6.99E-7	> 1.00E-4	> 1.00E-4
TK-10	0.767	1.667	1.596	1.620	1.208	1.073	0.646	92	95	49	34	-16	9.52E-7	4.81E-5	> 1.00E-4
UO-31	0.758	2.109	2.030	1.978	1.341	1.056	1.193	94	90	43	22	32	7.16E-7	> 1.00E-4	> 1.00E-4
Prostate Cancer															
PC-3	0.520	1.885	1.840	1.738	0.900	0.720	0.805	97	89	28	15	21	4.35E-7	> 1.00E-4	> 1.00E-4
DU-145	0.421	1.644	1.722	1.607	0.575	0.287	0.349	106	97	13	-32	-17	3.60E-7	1.92E-6	> 1.00E-4
Breast Cancer															
MCF7	0.581	2.760	2.641	2.494	1.100	0.945	0.991	95	88	24	17	19	3.90E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.666	1.544	1.528	1.449	0.866	0.723	0.572	98	89	23	6	-14	3.88E-7	2.07E-5	> 1.00E-4
HS 578T	0.818	1.621	1.594	1.520	0.951	0.999	0.708	97	87	17	23	-14	3.37E-7	4.22E-5	> 1.00E-4
BT-549	0.988	2.091	1.974	1.858	1.507	1.155	0.952	89	79	47	15	-4	8.09E-7	6.39E-5	> 1.00E-4
T-47D	0.814	1.601	1.575	1.465	1.092	1.224	1.133	97	83	35	52	41	.	> 1.00E-4	> 1.00E-4
MDA-MB-468	0.871	1.862	1.833	1.757	0.898	0.798	0.496	97	89	3	-8	-43	2.85E-7	1.74E-6	> 1.00E-4



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 818402 / 1

Experiment ID : 1911NS88

Test Type : 08

Report Date : December 26, 2019


Test Date : November 04, 2019

QNS :










COMI : GOA-13

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Log10 Concentration										GI50	TGI	LC50		
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0				
Leukemia															
CCRF-CEM	0.560	2.590	2.493	2.491	0.877	0.730	0.505	95	95	16	8	-10	3.69E-7	2.87E-5	> 1.00E-4
HL-60(TB)	0.917	3.342	3.259	3.319	0.883	0.749	0.605	97	99	-4	-18	-34	3.00E-7	9.20E-7	> 1.00E-4
K-562	0.194	2.184	2.123	1.907	0.458	0.407	0.284	97	86	13	11	4	3.13E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.642	2.853	2.878	2.928	1.358	1.377	0.787	101	103	32	33	7	5.65E-7	> 1.00E-4	> 1.00E-4
RPMI-8226	0.911	2.514	2.398	2.431	1.156	1.079	0.867	93	95	15	10	-5	3.66E-7	4.80E-5	> 1.00E-4
SR	0.388	2.216	2.048	1.885	0.694	0.610	0.428	91	82	17	12	2	3.09E-7	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.525	2.468	2.423	1.416	1.190	0.844	97	95	46	35	19	8.41E-7	> 1.00E-4	> 1.00E-4
EKVX	0.823	2.203	2.132	2.126	1.762	1.394	1.114	95	94	68	41	21	4.74E-6	> 1.00E-4	> 1.00E-4
HOP-62	0.655	1.900	1.766	1.750	1.195	1.069	0.305	89	88	43	33	-53	7.10E-7	2.42E-5	9.13E-5
HOP-92	1.228	1.937	1.849	1.752	1.500	1.447	0.862	88	74	38	31	-30	4.71E-7	3.23E-5	> 1.00E-4
NCI-H226	1.361	2.419	2.410	2.368	1.665	1.633	1.293	99	95	29	26	-5	4.78E-7	6.86E-5	> 1.00E-4
NCI-H23	0.582	1.887	1.879	1.827	1.177	1.037	0.280	99	95	46	35	-52	8.15E-7	2.52E-5	9.51E-5
NCI-H322M	0.918	2.231	2.139	2.107	1.430	1.466	1.039	93	91	39	42	9	6.12E-7	> 1.00E-4	> 1.00E-4
NCI-H460	0.404	3.214	3.245	3.252	0.805	0.787	0.515	101	101	14	14	4	3.89E-7	> 1.00E-4	> 1.00E-4
NCI-H522	1.037	2.650	2.505	2.419	1.309	1.176	0.808	91	86	17	9	-22	3.30E-7	1.90E-5	> 1.00E-4
Colon Cancer															
COLO 205	0.437	1.873	1.884	1.876	0.846	0.587	0.395	101	100	28	10	-10	5.01E-7	3.31E-5	> 1.00E-4
HCC-2998	0.648	1.877	1.876	1.842	1.319	0.888	0.469	100	97	55	20	-28	1.35E-6	2.59E-5	> 1.00E-4
HCT-116	0.285	2.383	2.335	2.258	0.825	0.549	0.259	98	94	26	13	-9	4.41E-7	3.80E-5	> 1.00E-4
HCT-15	0.234	1.720	1.636	1.634	0.537	0.406	0.329	94	94	20	12	6	3.97E-7	> 1.00E-4	> 1.00E-4
HT29	0.226	1.741	1.659	1.701	0.432	0.355	0.374	95	97	14	8	10	3.67E-7	> 1.00E-4	> 1.00E-4
KM12	0.874	3.366	3.368	3.332	1.610	1.430	1.123	100	99	30	22	10	5.05E-7	> 1.00E-4	> 1.00E-4
SW-620	0.358	2.688	2.664	2.524	0.839	0.835	0.826	99	93	21	20	20	3.93E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	1.102	2.804	2.730	2.557	2.071	2.015	0.814	96	86	57	54	-26	1.11E-5	4.70E-5	> 1.00E-4
SF-295	1.271	3.229	3.188	3.176	1.874	1.522	0.464	98	97	31	13	-64	5.14E-7	1.47E-5	6.65E-5
SF-539	0.781	2.461	2.432	2.318	0.908	0.636	0.172	98	91	8	-19	-78	3.12E-7	1.94E-6	3.38E-5
SNB-19	0.769	2.478	2.427	2.368	1.502	1.418	0.572	97	94	43	38	-26	7.24E-7	3.95E-5	> 1.00E-4
SNB-75	1.046	1.545	1.107	1.123	0.803	0.636	0.147	12	15	-23	-39	-86	< 1.00E-8	2.51E-7	1.70E-5
U251	0.446	2.054	1.961	1.923	1.033	0.867	0.243	94	92	37	26	-46	5.70E-7	2.32E-5	> 1.00E-4
Melanoma															
LOX IMVI	0.616	2.992	2.954	2.858	1.619	1.485	0.457	98	94	42	37	-26	7.09E-7	3.85E-5	> 1.00E-4
MALME-3M	0.634	1.254	1.217	1.136	0.872	0.808	0.462	94	81	38	28	-27	5.32E-7	3.23E-5	> 1.00E-4
M14	0.419	1.683	1.607	1.562	0.580	0.331	0.268	94	90	13	-21	-36	3.31E-7	2.37E-6	> 1.00E-4
MDA-MB-435	0.508	2.515	2.457	1.974	0.200	0.203	0.193	97	73	-61	-60	-62	1.49E-7	3.52E-7	8.33E-7
SK-MEL-2	1.085	2.871	2.841	2.818	2.015	1.855	0.694	98	97	52	43	-36	1.71E-6	3.51E-5	> 1.00E-4
SK-MEL-28	0.703	1.896	1.909	1.787	1.291	1.207	0.832	101	91	49	42	11	9.59E-7	> 1.00E-4	> 1.00E-4
SK-MEL-5	1.246	3.198	3.175	3.146	1.738	1.853	1.691	99	97	25	31	23	4.53E-7	> 1.00E-4	> 1.00E-4
UACC-257	0.795	2.114	2.033	1.994	1.558	1.539	1.421	94	91	58	56	47	5.20E-5	> 1.00E-4	> 1.00E-4
UACC-62	0.953	2.813	2.750	2.616	1.427	1.414	0.643	97	89	25	25	-33	4.14E-7	2.70E-5	> 1.00E-4
Ovarian Cancer															
IGROV1	0.474	1.985	1.940	1.883	1.052	0.870	0.345	97	93	38	26	-27	6.12E-7	3.09E-5	> 1.00E-4
OVCAR-3	0.561	1.875	1.885	1.846	0.584	0.400	0.117	101	98	2	-29	-79	3.15E-7	1.14E-6	2.64E-5
OVCAR-4	1.073	2.072	2.104	2.065	1.695	1.696	1.670	103	99	62	62	60	> 1.00E-4	> 1.00E-4	> 1.00E-4
OVCAR-5	0.576	1.618	1.584	1.561	1.150	1.004	0.672	97	95	55	41	9	2.29E-6	> 1.00E-4	> 1.00E-4
OVCAR-8	0.563	2.699	2.663	2.607	1.430	1.230	0.636	98	96	41	31	3	6.74E-7	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.593	2.115	2.038	2.085	1.506	1.201	0.875	95	98	60	40	18	3.14E-6	> 1.00E-4	> 1.00E-4
SK-OV-3	0.832	1.810	1.755	1.758	1.277	1.236	0.493	94	95	46	41	-41	8.11E-7	3.19E-5	> 1.00E-4
Renal Cancer															
786-0	0.741	2.629	2.611	2.556	1.391	1.275	0.292	99	96	34	28	-61	5.59E-7	2.08E-5	7.59E-5
A498	1.676	2.301	2.137	2.115	1.477	1.309	0.791	74	70	-12	-22	-53	1.76E-7	7.16E-7	8.10E-5
ACHN	0.544	2.350	2.292	2.259	1.305	1.306	0.628	97	95	42	42	5	7.10E-7	> 1.00E-4	> 1.00E-4
CAKI-1	1.234	3.022	2.847	2.633	1.791	1.720	1.166	90	78	31	27	-6	3.98E-7	6.78E-5	> 1.00E-4
RXF 393	0.955	1.832	1.790	1.771	0.961	0.835	0.258	95	93	1	-13	-73	2.92E-7	1.13E-6	4.16E-5
SN12C	0.566	2.298	2.147	2.188	1.254	1.208	0.665	91	94	40	37	6	6.45E-7	> 1.00E-4	> 1.00E-4
TK-10	1.066	1.936	1.826	1.804	1.687	1.599	0.643	87	85	71	61	-40	1.29E-5	4.04E-5	> 1.00E-4
UO-31	1.009	2.241	2.029	1.975	1.566	1.408	1.233	83	78	45	32	18	7.15E-7	> 1.00E-4	> 1.00E-4
Prostate Cancer															
PC-3	0.532	1.620	1.543	1.459	0.801	0.704	0.614	93	85	25	16	8	3.81E-7	> 1.00E-4	> 1.00E-4
DU-145	0.477	2.109	2.087	2.056	0.787	0.638	0.411	99	97	19	10	-14	3.99E-7	2.60E-5	> 1.00E-4
Breast Cancer															
MCF7	0.406	2.087	1.906	1.965	0.694	0.697	0.556	89	93	17	17	9	3.67E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.812	2.124	2.091	2.052	1.492	1.332	0.749	97	95	52	40	-8	1.41E-6	6.84E-5	> 1.00E-4
HS 578T	1.691	2.768	2.736	2.645	1.980	1.866	1.410	97	89	27	16	-17	4.21E-7	3.12E-5	> 1.00E-4
BT-549	1.314	2.366	2.289	2.240	1.839	1.617	0.950	93	88	50	29	-28	9.92E-7	3.23E-5	> 1.00E-4
T-47D	0.831	1.857	1.745	1.679	1.093	1.178	0.975	89	83	26	34	14	3.73E-7	> 1.00E-4	> 1.00E-4
MDA-MB-468	0.946	1.663	1.621	1.595	1.021	0.944	0.612	94	90	10	.	-35	3.20E-7	9.44E-6	> 1.00E-4












CN1C(=O)c2ccccc2C1=NC(=O)c3nc4c(nc(=O)n4C5=CC=CC=C5)nc(=O)n3C6=CC=CC=C6

5f

SSPL : 1AMN

Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration										GI50	TGI	LC50
			Mean Optical Densities					Percent Growth							
			-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.560	2.820	2.686	2.737	1.511	0.804	0.624	94	96	42	11	3	7.15E-7	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.917	3.355	3.316	3.347	0.865	0.683	0.569	98	100	-6	-26	-38	2.96E-7	8.83E-7	> 1.00E-4
K-562	0.194	2.066	1.865	1.880	0.407	0.259	0.224	89	90	11	3	2	3.23E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.642	2.815	2.695	2.773	1.607	0.868	0.690	94	98	44	10	2	7.87E-7	> 1.00E-4	> 1.00E-4
RPMI-8226	0.911	2.720	2.523	2.600	1.651	1.064	0.741	89	93	41	8	-19	6.71E-7	2.05E-5	> 1.00E-4
SR	0.388	2.211	1.976	1.824	0.652	0.520	0.410	87	79	14	7	1	2.80E-7	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.552	2.363	2.442	1.561	0.974	0.851	91	95	53	25	19	1.24E-6	> 1.00E-4	> 1.00E-4
EKVX	0.823	2.246	2.113	2.197	1.684	1.314	1.114	91	97	60	35	20	2.53E-6	> 1.00E-4	> 1.00E-4
HOP-62	0.655	1.918	1.752	1.872	1.343	1.083	0.805	87	96	54	34	12	1.65E-6	> 1.00E-4	> 1.00E-4
HOP-92	1.228	2.087	1.901	1.830	1.542	1.549	1.323	78	70	37	37	11	3.98E-7	> 1.00E-4	> 1.00E-4
NCI-H226	1.361	2.410	2.366	2.361	1.720	1.516	1.387	96	95	34	15	2	5.51E-7	> 1.00E-4	> 1.00E-4
NCI-H23	0.582	1.899	1.848	1.830	1.418	1.022	0.784	96	95	63	33	15	2.80E-6	> 1.00E-4	> 1.00E-4
NCI-H322M	0.918	2.244	2.141	2.240	1.820	1.506	1.324	92	100	68	44	31	5.75E-6	> 1.00E-4	> 1.00E-4
NCI-H460	0.404	3.221	3.218	3.231	1.516	0.597	0.490	100	100	39	7	3	6.72E-7	> 1.00E-4	> 1.00E-4
NCI-H522	1.037	2.645	2.419	2.439	1.486	1.173	0.877	86	87	28	8	-15	4.24E-7	2.26E-5	> 1.00E-4
Colon Cancer															
COLO 205	0.437	1.909	1.856	1.920	1.029	0.510	0.429	96	101	40	5	-2	6.89E-7	5.38E-5	> 1.00E-4
HCC-2998	0.648	1.924	1.728	1.806	1.432	0.688	0.669	85	91	61	3	2	1.57E-6	> 1.00E-4	> 1.00E-4
HCT-116	0.285	2.435	2.361	2.503	0.803	0.382	0.252	97	103	24	4	-12	4.70E-7	1.90E-5	> 1.00E-4
HCT-15	0.234	1.713	1.645	1.710	0.649	0.376	0.319	95	100	28	10	6	4.94E-7	> 1.00E-4	> 1.00E-4
HT29	0.226	1.817	1.711	1.762	0.534	0.354	0.282	93	97	19	8	3	4.01E-7	> 1.00E-4	> 1.00E-4
KM12															



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 818393 / 1

Experiment ID : 1911NS88

Test Type : 08

Report Date : December 26, 2019


Test Date : November 04, 2019

QNS :










COMI : IA-35

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Log10 Concentration											GI50	TGI	LC50	
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.560	2.760	2.778	2.730	1.072	0.809	0.781	101	99	23	11	10	4.42E-7	> 1.00E-4	> 1.00E-4
HL-60(TB)	0.917	3.367	3.341	3.374	0.943	0.784	0.684	99	100	1	-15	-25	3.21E-7	1.17E-6	> 1.00E-4
K-562	0.194	2.241	2.225	2.051	0.463	0.373	0.410	99	91	13	9	11	3.35E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.642	2.953	2.982	2.992	1.738	0.967	1.127	101	102	47	14	21	8.97E-7	> 1.00E-4	> 1.00E-4
RPMI-8226	0.911	2.697	2.656	2.652	1.330	1.094	1.112	98	97	23	10	11	4.38E-7	> 1.00E-4	> 1.00E-4
SR	0.388	2.290	2.157	2.115	0.694	0.590	0.614	93	91	16	11	12	3.52E-7	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.540	2.444	2.418	1.349	0.939	0.788	95	94	43	23	16	7.24E-7	> 1.00E-4	> 1.00E-4
EKVX	0.823	2.254	2.084	2.098	1.433	1.273	1.158	88	89	43	31	23	6.93E-7	> 1.00E-4	> 1.00E-4
HOP-62	0.655	1.920	1.837	1.761	1.188	0.928	0.257	93	87	42	22	-61	6.70E-7	1.83E-5	7.40E-5
HOP-92	1.228	2.030	1.938	1.827	1.614	1.273	0.990	88	75	48	6	-19	8.46E-7	1.67E-5	> 1.00E-4
NCI-H226	1.361	2.418	2.347	2.362	1.680	1.327	1.213	93	95	30	-2	-11	4.93E-7	8.38E-6	> 1.00E-4
NCI-H23	0.582	1.873	1.811	1.775	1.110	0.731	0.267	95	92	41	12	-54	6.66E-7	1.50E-5	8.65E-5
NCI-H322M	0.918	2.258	2.180	2.129	1.507	1.419	1.361	94	90	44	37	33	7.41E-7	> 1.00E-4	> 1.00E-4
NCI-H460	0.404	3.213	3.230	3.206	0.910	0.523	0.447	101	100	18	4	2	4.06E-7	> 1.00E-4	> 1.00E-4
NCI-H522	1.037	2.615	2.442	2.395	1.264	0.966	0.762	89	86	14	-7	-27	3.19E-7	4.76E-6	> 1.00E-4
Colon Cancer															
COLO 205	0.437	1.818	1.804	1.795	0.796	0.371	0.309	99	98	26	-15	-29	4.66E-7	4.29E-6	> 1.00E-4
HCC-2998	0.648	1.772	1.722	1.682	1.169	0.695	0.640	96	92	46	4	-1	8.31E-7	5.89E-5	> 1.00E-4
HCT-116	0.285	2.573	2.507	2.406	0.813	0.484	0.257	97	93	23	9	-10	4.10E-7	2.94E-5	> 1.00E-4
HCT-15	0.234	1.782	1.756	1.700	0.527	0.321	0.253	98	95	19	6	1	3.89E-7	> 1.00E-4	> 1.00E-4
HT29	0.226	1.725	1.684	1.696	0.366	0.341	0.338	97	98	9	8	7	3.48E-7	> 1.00E-4	> 1.00E-4
KM12	0.874	3.353	3.352	3.332	1.634	1.198	0.894	100	99	31	13	1	5.22E-7	> 1.00E-4	> 1.00E-4
SW-620	0.358	2.710	2.632	2.594	0.923	0.942	0.785	97	95	24	25	18	4.31E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	1.102	2.791	2.681	2.586	2.121	1.797	1.185	94	88	60	41	5	3.46E-6	> 1.00E-4	> 1.00E-4
SF-295	1.271	3.259	3.169	3.170	1.698	1.249	0.379	95	96	21	-2	-70	4.12E-7	8.42E-6	5.07E-5
SF-539	0.781	2.467	2.372	2.347	0.781	0.489	0.087	94	93	.	-37	-89	2.89E-7	9.98E-7	1.76E-5
SNB-19	0.769	2.537	2.455	2.422	1.599	1.371	0.757	95	93	47	34	-2	8.59E-7	9.00E-5	> 1.00E-4
SNB-75	1.046	1.797	1.418	1.514	1.049	1.154	0.299	49	62	.	14	-71	.	1.47E-5	5.62E-5
U251	0.446	2.097	2.023	1.968	1.059	0.806	0.330	96	92	37	22	-26	5.83E-7	2.86E-5	> 1.00E-4
Melanoma															
LOX IMVI	0.616	3.004	2.948	2.875	1.649	0.927	0.539	98	95	43	13	-13	7.39E-7	3.24E-5	> 1.00E-4
MALME-3M	0.634	1.292	1.239	1.193	0.894	0.759	0.677	92	85	39	19	6	5.87E-7	> 1.00E-4	> 1.00E-4
M14	0.419	1.893	1.824	1.760	0.651	0.563	0.372	95	91	16	10	-11	3.50E-7	2.90E-5	> 1.00E-4
MDA-MB-435	0.508	2.590	2.514	2.375	0.256	0.404	0.268	96	90	-50	-20	-47	1.93E-7	4.40E-7	> 1.00E-4
SK-MEL-2	1.085	2.846	2.770	2.790	2.016	1.560	0.850	96	97	53	27	-22	1.29E-6	3.59E-5	> 1.00E-4
SK-MEL-28	0.703	1.910	1.900	1.820	1.291	1.173	0.930	99	93	49	39	19	9.35E-7	> 1.00E-4	> 1.00E-4
SK-MEL-5	1.246	3.264	3.273	3.267	1.833	1.073	0.986	100	100	29	-14	-21	5.08E-7	4.75E-6	> 1.00E-4
UACC-257	0.795	2.145	2.081	2.054	1.598	1.562	1.347	95	93	59	57	41	2.68E-5	> 1.00E-4	> 1.00E-4
UACC-62	0.953	2.875	2.796	2.762	1.547	1.354	0.701	96	94	31	21	-26	4.99E-7	2.76E-5	> 1.00E-4
Ovarian Cancer															
IGROV1	0.474	2.032	2.021	1.930	1.082	0.678	0.438	99	93	39	13	-8	6.28E-7	4.29E-5	> 1.00E-4
OVCAR-3	0.561	1.870	1.873	1.812	0.578	0.358	0.231	100	96	1	-36	-59	3.04E-7	1.08E-6	4.08E-5
OVCAR-4	1.073	2.143	2.149	2.079	1.787	1.469	1.645	101	94	67	37	53	.	> 1.00E-4	> 1.00E-4
OVCAR-5	0.576	1.662	1.594	1.593	1.177	0.927	0.748	94	94	55	32	16	1.71E-6	> 1.00E-4	> 1.00E-4
OVCAR-8	0.563	2.682	2.643	2.597	1.353	0.901	0.803	98	96	37	16	11	6.07E-7	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.593	2.069	2.060	1.964	0.895	0.612	0.425	99	93	20	1	-28	3.90E-7	1.11E-5	> 1.00E-4
SK-OV-3	0.832	1.779	1.806	1.751	1.285	1.012	0.669	103	97	48	19	-20	9.02E-7	3.10E-5	> 1.00E-4
Renal Cancer															
786-0	0.741	2.832	2.763	2.697	1.635	0.912	0.250	97	94	43	8	-66	7.19E-7	1.29E-5	6.05E-5
A498	1.676	2.325	2.036	2.100	1.443	1.230	0.645	55	65	-14	-27	-62	1.56E-7	6.67E-7	4.67E-5
ACHN	0.544	2.348	2.343	2.348	1.411	0.988	0.660	100	100	48	25	6	9.16E-7	> 1.00E-4	> 1.00E-4
CAKI-1	1.234	3.105	2.928	2.828	1.803	1.716	1.055	91	85	30	26	-15	4.39E-7	4.36E-5	> 1.00E-4
RXF 393	0.955	1.770	1.803	1.753	0.863	0.836	0.179	104	98	-10	-13	-81	2.79E-7	8.14E-7	3.51E-5
SN12C	0.566	2.289	2.225	2.161	1.339	0.951	0.829	96	93	45	22	15	7.80E-7	> 1.00E-4	> 1.00E-4
TK-10	1.066	1.960	1.822	1.820	1.638	1.401	0.296	85	84	64	37	-72	3.38E-6	2.20E-5	6.27E-5
UO-31	1.009	2.211	2.016	1.945	1.524	1.338	1.266	84	78	43	27	21	6.24E-7	> 1.00E-4	> 1.00E-4
Prostate Cancer															
PC-3	0.532	1.656	1.610	1.592	0.890	0.691	0.654	96	94	32	14	11	5.12E-7	> 1.00E-4	> 1.00E-4
DU-145	0.477	2.049	2.088	2.042	0.850	0.561	0.349	102	100	24	5	-27	4.50E-7	1.46E-5	> 1.00E-4
Breast Cancer															
MCF7	0.406	2.131	2.019	1.981	0.762	0.644	0.742	93	91	21	14	19	3.84E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.812	2.221	2.237	2.159	1.625	1.175	0.746	101	96	58	26	-8	1.74E-6	5.76E-5	> 1.00E-4
HS 578T	1.691	2.809	2.735	2.676	2.012	1.862	1.461	93	88	29	15	-14	4.38E-7	3.38E-5	> 1.00E-4
BT-549	1.314	2.507	2.453	2.455	2.004	1.360	0.963	95	96	58	4	-27	1.40E-6	1.33E-5	> 1.00E-4
T-47D	0.831	1.836	1.808	1.664	1.157	1.385	1.361	97	83	32	55	53	.	> 1.00E-4	> 1.00E-4
MDA-MB-468	0.946	1.670	1.640	1.615	0.973	0.931	0.740	96	92	4	-2	-22	3.00E-7	4.99E-6	> 1.00E-4



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 809872 / 1

Experiment ID : 1812NS43

Test Type : 08

Report Date : January 09, 2019


Test Date : December 17, 2018

QNS :










COMI : IA626

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration						Percent Growth					GI50	TGI	LC50
			-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0				
Leukemia																
CCRF-CEM	0.328	1.895	1.955	1.933	0.721	0.445	0.382	104	102	25	7	3	4.76E-7	> 1.00E-4	> 1.00E-4	
HL-60(TB)	1.047	3.405	3.331	3.328	0.922	0.538	0.441	97	97	-12	-49	-58	2.69E-7	7.77E-7	1.41E-5	
K-562	0.285	2.594	2.615	2.434	0.694	0.442	0.394	101	93	18	7	5	3.73E-7	> 1.00E-4	> 1.00E-4	
MOLT-4	0.625	2.868	2.955	2.849	1.763	0.959	0.926	104	99	51	15	13	1.05E-6	> 1.00E-4	> 1.00E-4	
RPMI-8226	0.725	2.289	2.289	2.268	1.158	0.582	0.409	100	99	28	-20	-44	4.85E-7	3.84E-6	> 1.00E-4	
SR	0.400	1.256	1.351	1.249	0.551	0.442	0.356	111	99	18	5	-11	4.01E-7	2.02E-5	> 1.00E-4	
Non-Small Cell Lung Cancer																
A549/ATCC	0.310	1.301	1.161	1.160	0.796	0.395	0.154	86	86	49	9	-50	9.39E-7	1.40E-5	9.81E-5	
EKVX	0.678	1.962	1.887	1.799	1.322	1.027	0.907	94	87	50	27	18	1.01E-6	> 1.00E-4	> 1.00E-4	
HOP-62	0.665	2.312	2.207	2.145	1.290	1.100	0.100	94	90	38	26	-85	5.85E-7	1.73E-5	4.85E-5	
HOP-92	0.960	1.641	1.568	1.410	1.315	1.163	0.231	89	66	52	30	-76	1.24E-6	1.91E-5	5.69E-5	
NCI-H226	0.875	2.102	2.023	2.044	1.647	1.386	1.080	94	95	63	42	17	4.03E-6	> 1.00E-4	> 1.00E-4	
NCI-H23	0.569	1.995	1.924	1.909	1.230	0.934	0.066	95	94	46	26	-88	8.38E-7	1.68E-5	4.60E-5	
NCI-H322M	0.808	2.092	1.996	1.984	1.459	1.450	0.834	93	92	51	50	2	1.00E-5	> 1.00E-4	> 1.00E-4	
NCI-H460	0.185	1.766	1.824	1.803	0.492	0.269	0.115	104	102	19	5	-38	4.28E-7	1.33E-5	> 1.00E-4	
NCI-H522	0.757	2.174	1.994	2.092	1.089	0.653	0.223	87	94	23	-14	-71	4.21E-7	4.27E-6	4.34E-5	
Colon Cancer																
COLO 205	0.396	1.520	1.528	1.445	0.853	0.398	0.365	101	93	41	.	-8	6.65E-7	1.04E-5	> 1.00E-4	
HCC-2998	0.868	2.691	2.741	2.586	1.909	1.112	0.713	103	94	57	13	-18	1.45E-6	2.68E-5	> 1.00E-4	
HCT-116	0.162	1.807	1.729	1.719	0.472	0.219	0.038	95	95	19	3	-77	3.88E-7	1.10E-5	4.63E-5	
HCT-15	0.291	1.496	1.403	1.448	0.562	0.400	0.346	92	96	22	9	5	4.22E-7	> 1.00E-4	> 1.00E-4	
HT29	0.193	1.364	1.334	1.287	0.267	0.203	0.114	97	93	6	1	-41	3.15E-7	1.05E-5	> 1.00E-4	
KM12	0.396	1.892	1.844	1.740	0.709	0.563	0.204	97	90	21	11	-49	3.79E-7	1.54E-5	> 1.00E-4	
SW-620	0.248	1.811	1.785	1.716	0.611	0.699	0.709	98	94	23	29	29	4.18E-7	> 1.00E-4	> 1.00E-4	
CNS Cancer																
SF-268	0.567	1.968	1.936	1.815	1.138	0.834	0.201	98	89	41	19	-65	6.44E-7	1.69E-5	6.70E-5	
SF-295	1.110	2.961	2.852	2.790	1.637	1.174	0.233	94	91	28	3	-79	4.51E-7	1.10E-5	4.45E-5	
SF-539	1.011	2.488	2.339	2.284	0.888	0.712	0.016	90	86	-12	-30	-98	2.33E-7	7.51E-7	1.98E-5	
SNB-19	0.635	2.119	2.032	1.995	1.351	1.109	0.352	94	92	48	32	-45	9.10E-7	2.61E-5	> 1.00E-4	
SNB-75	1.546	2.493	2.209	2.158	1.387	1.113	0.413	70	65	-10	-28	-73	1.57E-7	7.28E-7	3.06E-5	
U251	0.296	1.176	1.108	1.161	0.554	0.330	0.045	92	98	29	4	-85	5.02E-7	1.11E-5	4.05E-5	
Melanoma																
LOX IMVI	0.431	2.926	2.835	2.655	1.567	0.949	0.340	96	89	46	21	-21	7.90E-7	3.13E-5	> 1.00E-4	
MALME-3M	0.790	1.789	1.708	1.637	1.190	1.121	0.506	92	85	40	33	-36	5.99E-7	3.02E-5	> 1.00E-4	
M14	0.457	1.962	2.029	1.998	0.827	0.509	0.284	104	102	25	3	-38	4.71E-7	1.21E-5	> 1.00E-4	
MDA-MB-435	0.587	2.521	2.458	2.338	0.258	0.364	0.156	97	91	-56	-38	-74	1.89E-7	4.15E-7	.	
SK-MEL-2	0.834	2.016	1.997	1.892	1.381	1.053	0.084	98	90	46	19	-90	8.21E-7	1.48E-5	4.28E-5	
SK-MEL-28	0.683	2.046	2.033	1.950	1.350	1.245	0.504	99	93	49	41	-26	9.47E-7	4.08E-5	> 1.00E-4	
SK-MEL-5	0.792	2.642	2.590	2.476	1.192	0.715	0.086	97	91	22	-10	-89	3.90E-7	4.89E-6	3.21E-5	
UACC-257	0.742	1.463	1.316	1.385	1.053	0.694	0.579	80	89	43	-6	-22	7.07E-7	7.40E-6	> 1.00E-4	
UACC-62	0.869	2.766	2.730	2.631	1.418	1.301	0.255	98	93	29	23	-71	4.68E-7	1.75E-5	6.00E-5	
Ovarian Cancer																
IGROV1	0.811	2.535	2.492	2.421	1.585	0.978	0.433	97	93	45	10	-47	7.84E-7	1.49E-5	> 1.00E-4	
OVCAR-3	0.328	1.122	1.125	1.117	0.310	0.287	0.062	100	99	-5	-13	-81	2.96E-7	8.86E-7	3.50E-5	
OVCAR-4	0.653	1.572	1.555	1.439	1.095	0.723	0.429	98	86	48	8	-34	8.91E-7	1.52E-5	> 1.00E-4	
OVCAR-5	0.629	1.409	1.387	1.335	1.049	0.798	0.521	97	91	54	22	-17	1.31E-6	3.60E-5	> 1.00E-4	
OVCAR-8	0.439	1.385	1.361	1.312	0.850	0.464	0.144	97	92	43	3	-67	7.35E-7	1.09E-5	5.65E-5	
NCI/ADR-RES	0.650	2.120	2.028	1.931	0.946	0.721	0.413	94	87	20	5	-37	3.59E-7	1.31E-5	> 1.00E-4	
SK-OV-3	0.776	1.988	1.896	1.847	1.311	1.004	0.072	92	88	44	19	-91	7.37E-7	1.49E-5	4.25E-5	
Renal Cancer																
786-0	0.617	2.454	2.351	2.235	1.539	1.215	0.114	94	88	50	33	-82	1.02E-6	1.93E-5	5.29E-5	
A498	1.583	2.275	2.194	2.084	1.437	1.284	0.526	88	72	-9	-19	-67	1.88E-7	7.70E-7	4.46E-5	
ACHN	0.297	1.168	1.149	1.132	0.573	0.482	0.102	98	96	32	21	-66	5.18E-7	1.75E-5	6.60E-5	
CAKI-1	1.018	2.764	2.560	2.482	1.518	1.359	0.410	98	84	29	20	-60	4.10E-7	1.76E-5	7.54E-5	
RXF 393	1.326	1.971	1.886	1.892	1.375	1.444	0.247	87	88	8	18	-81	2.95E-7	1.53E-5	4.84E-5	
SN12C	0.728	2.737	2.667	2.622	1.747	1.036	0.506	96	94	51	15	-30	1.05E-6	2.16E-5	> 1.00E-4	
TK-10	0.824	2.165	1.998	1.947	1.497	1.294	0.090	88	84	50	35	-89	1.03E-6	1.92E-5	4.84E-5	
UO-31	0.924	2.090	1.911	1.933	1.438	1.199	0.365	85	87	44	24	-61	7.25E-7	1.91E-5	7.49E-5	
Prostate Cancer																
PC-3	0.455	1.932	1.833	1.812	0.927	0.638	0.513	93	92	32	12	4	4.99E-7	> 1.00E-4	> 1.00E-4	
DU-145	0.363	1.483	1.544	1.452	0.683	0.400	0.194	105	97	29	3	-47	4.88E-7	1.16E-5	> 1.00E-4	
Breast Cancer																
MCF7	0.394	1.836	1.703	1.710	0.740	0.506	0.461	91	91	24	8	5	4.10E-7	> 1.00E-4	> 1.00E-4	
MDA-MB-231/ATCC	0.745	1.640	1.659	1.575	1.341	0.783	0.485	102	93	67	4	-35	1.85E-6	1.28E-5	> 1.00E-4	
HS 578T	0.921	1.950	1.890	1.877	1.175	1.023	0.968	94	93	25	10	5	4.25E-7	> 1.00E-4	> 1.00E-4	
BT-549	1.385	2.775	2.662	2.639	2.280	1.645	0.798	92	90	64	19	-42	2.07E-6	2.02E-5	> 1.00E-4	
T-47D	0.652	1.644	1.586	1.395	0.937	0.869	0.769	94	75	29	22	12	3.46E-7	> 1.00E-4	> 1.00E-4	
MDA-MB-468	0.819	1.808	1.759	1.733	1.010	0.803	0.550	95	92	19	-2	-33	3.80E-7	8.05E-6	> 1.00E-4	



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 803209 / 1

Experiment ID : 1802NS43

Test Type : 08

Report Date : March 20, 2018


Test Date : February 26, 2018

QNS :










COMI : IA36

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Log10 Concentration											GI50	TGI	LC50
	Time	Mean Optical Densities						Percent Growth						
	Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0		
Leukemia														
CCRF-CEM	0.635	3.210	3.124	2.860	0.920	0.819	0.672	97	86	11	7	1	3.04E-7	> 1.00E-4
HL-60(TB)	0.632	2.353	2.206	2.159	0.768	0.551	0.599	91	89	8	-13	-5	3.01E-7	> 1.00E-4
K-562	0.228	2.225	2.225	2.181	0.568	0.433	0.420	100	98	17	10	10	3.91E-7	> 1.00E-4
MOLT-4	0.898	3.175	3.149	3.161	2.080	1.357	1.418	99	99	52	20	23	1.15E-6	> 1.00E-4
RPMI-8226	0.798	2.553	2.549	2.507	1.069	0.753	0.890	100	97	15	-6	5	3.78E-7	> 1.00E-4
SR	0.536	2.649	2.447	2.383	0.877	0.805	0.822	90	87	16	13	14	3.35E-7	> 1.00E-4
Non-Small Cell Lung Cancer														
A549/ATCC	0.460	2.426	2.253	2.375	1.396	0.646	0.598	91	97	48	9	7	8.95E-7	> 1.00E-4
EKVX	0.837	2.518	2.374	2.369	1.686	1.524	1.395	91	91	51	41	33	1.13E-6	> 1.00E-4
HOP-62	0.592	2.275	2.259	2.237	1.266	0.833	0.492	99	98	40	14	-17	6.71E-7	> 1.00E-4
HOP-92	1.191	1.774	1.731	1.688	1.466	1.170	0.997	93	85	47	-2	-16	8.42E-7	> 1.00E-4
NCI-H226	1.176	2.631	2.517	2.445	2.367	1.475	1.387	92	87	82	21	15	3.31E-6	> 1.00E-4
NCI-H23	0.676	2.393	2.283	2.217	1.418	1.051	0.464	94	90	43	22	-31	7.15E-7	> 1.00E-4
NCI-H322M	0.806	1.934	1.886	1.849	1.289	0.974	1.241	96	92	43	15	39	7.17E-7	> 1.00E-4
NCI-H460	0.274	2.758	2.775	2.790	0.695	0.315	0.478	101	101	17	2	8	4.06E-7	> 1.00E-4
NCI-H522	0.767	2.011	1.814	1.820	0.670	0.527	0.550	84	85	-13	-31	-28	2.27E-7	> 1.00E-4
Colon Cancer														
COLO 205	0.400	1.583	1.647	1.584	0.565	0.366	0.306	105	100	14	-9	-24	3.81E-7	> 1.00E-4
HCC-2998	0.824	2.854	2.678	2.666	1.908	1.087	1.153	91	91	53	13	16	1.21E-6	> 1.00E-4
HCT-116	0.282	2.656	2.597	2.487	0.771	0.306	0.330	97	93	21	1	2	3.92E-7	> 1.00E-4
HCT-15	0.348	2.456	2.307	2.279	0.850	0.583	0.501	93	92	24	11	7	4.11E-7	> 1.00E-4
HT29	0.233	1.689	1.725	1.707	0.406	0.165	0.226	102	101	12	-29	-3	3.74E-7	> 1.00E-4
KM12	0.491	2.615	2.542	2.479	0.995	0.539	0.555	97	94	24	2	3	4.21E-7	> 1.00E-4
SW-620	0.205	1.563	1.503	1.498	0.518	0.515	0.544	96	95	23	23	25	4.23E-7	> 1.00E-4
CNS Cancer														
SF-268	0.664	2.356	2.238	2.189	1.451	1.049	0.686	93	90	46	23	1	8.31E-7	> 1.00E-4
SF-295	0.875	2.989	2.891	2.849	1.353	0.953	0.335	95	93	23	4	-62	4.10E-7	1.14E-5
SF-539	0.901	2.607	2.578	2.498	1.012	0.711	0.380	98	94	6	-21	-58	3.17E-7	1.72E-6
SNB-19	0.582	1.967	1.893	1.842	1.173	1.044	0.517	95	91	43	33	-11	7.04E-7	5.61E-5
SNB-75	0.792	1.776	1.634	1.636	1.035	0.830	0.174	86	86	25	4	-78	3.84E-7	1.11E-5
U251	0.345	1.888	1.861	1.846	0.749	0.382	0.187	98	97	26	2	-46	4.62E-7	1.12E-5
Melanoma														
LOX IMVI	0.365	2.684	2.585	2.563	1.333	0.581	0.557	96	95	42	9	8	6.99E-7	> 1.00E-4
MALME-3M	0.477	1.221	1.196	1.156	0.923	0.634	0.700	97	91	60	21	30	1.80E-6	> 1.00E-4
M14	0.379	1.833	1.760	1.735	0.545	0.488	0.385	95	93	11	7	.	3.38E-7	> 1.00E-4
MDA-MB-435	0.539	2.618	2.583	2.424	0.327	0.434	0.221	98	91	-39	-19	-59	2.05E-7	4.98E-7
SK-MEL-2	1.013	2.149	2.099	2.145	1.465	1.153	0.428	96	100	40	12	-58	6.75E-7	1.50E-5
SK-MEL-28	0.599	1.706	1.701	1.649	1.269	1.039	0.843	100	95	61	40	22	3.22E-6	> 1.00E-4
SK-MEL-5	0.788	3.204	3.114	3.097	1.335	0.396	0.690	96	96	23	-50	-12	4.21E-7	2.05E-6
UACC-257	1.038	2.534	2.476	2.460	1.713	1.715	1.425	96	95	45	45	26	7.99E-7	> 1.00E-4
UACC-62	0.952	3.097	2.968	2.971	1.695	1.245	0.861	94	94	35	14	-10	5.52E-7	3.86E-5
Ovarian Cancer														
IGROV1	0.563	1.835	1.817	1.763	1.092	0.678	0.697	99	94	42	9	10	6.91E-7	> 1.00E-4
OVCAR-3	0.428	1.556	1.561	1.546	0.546	0.353	0.173	100	99	10	-18	-60	3.58E-7	2.37E-6
OVCAR-4	0.707	2.024	1.949	1.949	1.466	0.871	1.151	94	94	58	12	34	1.47E-6	> 1.00E-4
OVCAR-5	0.504	1.715	1.667	1.679	1.069	0.710	0.678	96	97	47	17	14	8.56E-7	> 1.00E-4
OVCAR-8	0.465	2.111	2.114	2.140	1.089	0.618	0.664	100	102	38	9	12	6.46E-7	> 1.00E-4
NCI/ADR-RES	0.553	2.237	2.152	2.129	0.895	0.643	0.446	95	94	20	5	-19	3.93E-7	1.64E-5
SK-OV-3	0.841	2.025	2.043	2.010	1.400	0.714	0.780	102	99	47	-15	-7	8.83E-7	5.72E-6
Renal Cancer														
786-0	0.646	2.645	2.595	2.505	1.431	0.951	0.348	98	93	39	15	-46	6.31E-7	1.77E-5
A498	1.530	2.705	2.686	2.663	1.677	1.057	0.775	98	96	13	-31	-49	3.57E-7	1.94E-6
ACHN	0.374	1.622	1.619	1.629	1.008	0.487	0.461	100	101	51	9	7	1.05E-6	> 1.00E-4
CAKI-1	0.621	2.199	2.080	2.026	1.215	0.853	0.680	92	89	38	15	4	5.75E-7	> 1.00E-4
RXF 393	0.973	1.962	1.916	1.880	1.076	0.825	0.275	95	92	10	-15	-72	3.26E-7	2.54E-6
SN12C	0.490	1.973	1.937	1.892	1.111	0.727	0.807	98	95	42	16	21	7.00E-7	> 1.00E-4
TK-10	0.746	1.707	1.593	1.655	1.244	0.512	0.102	88	95	52	-31	-86	1.05E-6	4.19E-6
UO-31	0.468	1.480	1.346	1.314	0.931	0.353	0.675	87	84	46	-25	20	7.70E-7	.
Prostate Cancer														
PC-3	0.537	1.534	1.478	1.479	0.818	0.654	0.716	94	94	28	12	18	4.68E-7	> 1.00E-4
DU-145	0.372	1.796	1.805	1.777	0.692	0.408	0.317	101	99	22	2	-15	4.35E-7	1.39E-5
Breast Cancer														
MCF7	0.365	2.262	2.083	2.119	0.850	0.693	0.737	91	92	26	17	20	4.31E-7	> 1.00E-4
MDA-MB-231/ATCC	0.523	1.381	1.347	1.353	1.001	0.491	0.371	96	97	56	-6	-29	1.23E-6	7.96E-6
HS 578T	0.962	2.074	1.975	2.050	1.204	1.147	0.854	91	98	22	17	-11	4.25E-7	3.95E-5
BT-549	1.001	2.306	2.276	2.269	1.796	1.113	0.974	98	97	61	9	-3	1.62E-6	5.71E-5
T-47D	0.764	1.801	1.705	1.667	1.068	1.100	1.272	91	87	29	32	49	4.38E-7	> 1.00E-4
MDA-MB-468	0.937	2.261	2.149	2.066	1.245	1.141	0.557	92	85	23	15	-41	3.71E-7	1.89E-5



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 818413 / 1

Experiment ID : 1911NS88

Test Type : 08

Report Date : December 26, 2019


Test Date : November 04, 2019

QNS :










COMI : IA-756

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time	Log10 Concentration										GI50	TGI	LC50		
		Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia																
CCRF-CEM	0.560	2.604	2.575	2.535	0.952	0.784	0.729	99	97	19	11	8	4.00E-7	> 1.00E-4	> 1.00E-4	
HL-60(TB)	0.917	3.359	3.346	3.361	0.815	0.717	0.653	99	100	-11	-22	-29	2.82E-7	7.94E-7	> 1.00E-4	
K-562	0.194	2.143	2.129	1.994	0.458	0.364	0.349	99	92	14	9	8	3.45E-7	> 1.00E-4	> 1.00E-4	
MOLT-4	0.642	2.811	2.938	2.877	1.530	0.955	0.943	106	103	41	14	14	7.14E-7	> 1.00E-4	> 1.00E-4	
RPMI-8226	0.911	2.500	2.469	2.534	1.257	1.198	1.130	98	102	22	18	14	4.45E-7	> 1.00E-4	> 1.00E-4	
SR	0.388	2.355	2.215	2.143	0.659	0.624	0.634	93	89	14	12	12	3.31E-7	> 1.00E-4	> 1.00E-4	
Non-Small Cell Lung Cancer																
A549/ATCC	0.458	2.534	2.414	2.404	1.310	0.923	0.814	94	94	41	22	17	6.76E-7	> 1.00E-4	> 1.00E-4	
EKVX	0.823	2.251	2.220	2.196	1.564	1.509	1.439	98	96	52	48	43	3.10E-6	> 1.00E-4	> 1.00E-4	
HOP-62	0.655	1.942	1.858	1.794	1.207	1.029	0.415	93	88	43	29	-37	6.97E-7	2.77E-5	> 1.00E-4	
HOP-92	1.228	1.888	1.850	1.761	1.588	1.452	1.209	94	81	55	34	-2	1.67E-6	9.02E-5	> 1.00E-4	
NCI-H226	1.361	2.425	2.418	2.383	1.778	1.536	1.319	99	96	39	16	-3	6.45E-7	6.92E-5	> 1.00E-4	
NCI-H23	0.582	1.902	1.880	1.791	1.175	0.994	0.332	98	92	45	31	-43	7.78E-7	2.63E-5	> 1.00E-4	
NCI-H322M	0.918	2.298	2.212	2.148	1.454	1.533	1.361	94	89	39	45	32	6.00E-7	> 1.00E-4	> 1.00E-4	
NCI-H460	0.404	3.267	3.282	3.291	0.997	0.699	0.587	101	101	21	10	6	4.31E-7	> 1.00E-4	> 1.00E-4	
NCI-H522	1.037	2.630	2.523	2.439	1.362	1.170	1.010	93	88	20	8	-3	3.65E-7	5.78E-5	> 1.00E-4	
Colon Cancer																
COLO 205	0.437	1.739	1.716	1.728	0.751	0.412	0.510	98	99	24	-6	6	4.51E-7	.	> 1.00E-4	
HCC-2998	0.648	1.980	1.882	1.837	1.323	0.799	0.751	93	89	51	11	8	1.04E-6	> 1.00E-4	> 1.00E-4	
HCT-116	0.285	2.602	2.604	2.426	0.893	0.511	0.327	100	92	26	10	2	4.37E-7	> 1.00E-4	> 1.00E-4	
HCT-15	0.234	1.777	1.668	1.641	0.538	0.385	0.360	93	91	20	10	8	3.77E-7	> 1.00E-4	> 1.00E-4	
HT29	0.226	1.736	1.646	1.703	0.425	0.364	0.480	94	98	13	9	17	3.67E-7	> 1.00E-4	> 1.00E-4	
KM12	0.874	3.358	3.367	3.324	1.603	1.291	0.964	100	99	29	17	4	5.03E-7	> 1.00E-4	> 1.00E-4	
SW-620	0.358	2.788	2.729	2.668	0.988	0.987	0.915	98	95	26	26	23	4.48E-7	> 1.00E-4	> 1.00E-4	
CNS Cancer																
SF-268	1.102	2.854	2.780	2.639	2.222	2.126	1.441	96	88	64	58	19	1.64E-5	> 1.00E-4	> 1.00E-4	
SF-295	1.271	3.295	3.243	3.250	2.128	1.683	0.759	97	98	42	20	-40	7.28E-7	2.16E-5	> 1.00E-4	
SF-539	0.781	2.481	2.449	2.367	0.844	0.713	0.274	98	93	4	-9	-65	3.04E-7	1.98E-6	5.42E-5	
SNB-19	0.769	2.502	2.501	2.480	1.606	1.462	0.805	100	99	48	40	2	9.25E-7	> 1.00E-4	> 1.00E-4	
U251	0.446	2.036	1.978	1.865	1.060	0.832	0.240	96	89	39	24	-46	5.96E-7	2.21E-5	> 1.00E-4	
Melanoma																
LOX IMVI	0.616	3.028	2.985	2.903	1.679	1.365	0.624	98	95	44	31	.	7.64E-7	> 1.00E-4	> 1.00E-4	
MALME-3M	0.634	1.291	1.237	1.150	0.904	0.891	0.770	92	79	41	39	21	5.78E-7	> 1.00E-4	> 1.00E-4	
M14	0.419	1.840	1.798	1.756	0.663	0.575	0.426	97	94	17	11	.	3.74E-7	> 1.00E-4	> 1.00E-4	
MDA-MB-435	0.508	2.513	2.550	2.347	0.359	0.468	0.272	102	92	-29	-8	-46	2.21E-7	5.72E-7	> 1.00E-4	
SK-MEL-2	1.085	2.877	2.864	2.875	2.058	1.777	1.091	99	100	54	39	.	1.88E-6	> 1.00E-4	> 1.00E-4	
SK-MEL-28	0.703	1.930	1.911	1.803	1.246	1.231	0.922	98	90	44	43	18	7.48E-7	> 1.00E-4	> 1.00E-4	
SK-MEL-5	1.246	3.226	3.243	3.229	1.977	1.857	1.188	101	100	37	31	-5	6.20E-7	7.38E-5	> 1.00E-4	
UACC-257	0.795	2.022	1.948	1.907	1.470	1.514	1.245	94	91	55	59	37	2.46E-5	> 1.00E-4	> 1.00E-4	
UACC-62	0.953	2.865	2.821	2.729	1.598	1.610	0.838	98	93	34	34	-12	5.31E-7	5.50E-5	> 1.00E-4	
Ovarian Cancer																
IGROV1	0.474	2.098	2.068	2.008	1.114	0.765	0.467	98	94	39	18	-2	6.41E-7	8.29E-5	> 1.00E-4	
OVCAR-3	0.561	1.899	1.934	1.869	0.569	0.475	0.207	103	98	1	-15	-63	3.10E-7	1.08E-6	5.30E-5	
OVCAR-4	1.073	2.136	2.195	2.081	1.788	1.712	1.866	106	95	67	60	75	> 1.00E-4	> 1.00E-4	> 1.00E-4	
OVCAR-5	0.576	1.589	1.554	1.527	1.075	0.915	0.778	97	94	49	33	20	9.64E-7	> 1.00E-4	> 1.00E-4	
OVCAR-8	0.563	2.639	2.656	2.566	1.307	0.998	0.778	101	96	36	21	10	5.84E-7	> 1.00E-4	> 1.00E-4	
NCI/ADR-RES	0.593	2.063	2.095	2.001	1.042	0.727	0.535	102	96	31	9	-10	5.02E-7	3.03E-5	> 1.00E-4	
SK-OV-3	0.832	1.810	1.800	1.769	1.330	1.267	0.878	99	96	51	44	5	1.38E-6	> 1.00E-4	> 1.00E-4	
Renal Cancer																
786-O	0.741	2.722	2.667	2.590	1.617	1.413	0.416	97	93	44	34	-44	7.62E-7	2.73E-5	> 1.00E-4	
A498	1.676	2.303	2.154	2.067	1.459	1.311	0.874	76	62	-13	-22	-48	1.46E-7	6.73E-7	> 1.00E-4	
ACHN	0.544	2.331	2.297	2.289	1.360	1.186	0.623	98	98	46	36	4	8.25E-7	> 1.00E-4	> 1.00E-4	
CAKI-1	1.234	3.140	2.994	2.852	1.837	1.912	1.463	92	85	32	36	12	4.52E-7	> 1.00E-4	> 1.00E-4	
RXF 393	0.955	1.817	1.779	1.817	0.951	0.867	0.379	96	100	.	-9	-60	3.14E-7	9.89E-7	6.27E-5	
SN12C	0.566	2.264	2.174	2.161	1.346	1.151	0.932	95	94	46	34	22	8.21E-7	> 1.00E-4	> 1.00E-4	
TK-10	1.066	1.994	1.866	1.860	1.723	1.693	0.413	86	86	71	68	-61	1.37E-5	3.34E-5	8.17E-5	
UO-31	1.009	2.316	2.118	2.038	1.559	1.456	1.462	85	79	42	34	35	6.08E-7	> 1.00E-4	> 1.00E-4	
Prostate Cancer																
PC-3	0.532	1.592	1.499	1.537	0.869	0.747	0.782	91	95	32	20	24	5.14E-7	> 1.00E-4	> 1.00E-4	
DU-145	0.477	2.076	2.115	2.042	0.827	0.638	0.247	102	98	22	10	-48	4.26E-7	1.49E-5	> 1.00E-4	
Breast Cancer																
MCF7	0.406	2.194	2.047	2.036	0.853	0.750	0.866	92	91	25	19	26	4.19E-7	> 1.00E-4	> 1.00E-4	
MDA-MB-231/ATCC	0.812	2.218	2.260	2.148	1.603	1.247	0.657	103	95	56	31	-19	1.76E-6	4.15E-5	> 1.00E-4	
HS 578T	1.691	2.922	2.880	2.761	2.103	2.054	1.685	97	87	33	29	.	4.90E-7	9.73E-5	> 1.00E-4	
BT-549	1.314	2.444	2.407	2.302	1.948	1.386	0.898	97	87	56	6	-32	1.33E-6	1.47E-5	> 1.00E-4	
T-47D	0.831	1.803	1.803	1.699	1.204	1.361	1.405	100	89	38	55	59	.	> 1.00E-4	> 1.00E-4	
MDA-MB-468	0.946	1.535	1.518	1.530	0.965	0.862	0.655	97	99	3	-9	-31	3.26E-7	1.85E-6	> 1.00E-4	



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 809836 / 1

Experiment ID : 1812NS43

Test Type : 08

Report Date : January 09, 2019


Test Date : December 17, 2018

QNS :










COMI : MM-164

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time	Log10 Concentration										GI50	TGI	LC50	
		Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.328	1.752	1.739	1.766	0.918	0.299	0.419	99	101	41	-9	6	7.18E-7	.	> 1.00E-4
HL-60(TB)	1.047	3.368	3.303	3.310	2.053	0.354	0.456	97	98	43	-66	-56	7.54E-7	2.49E-6	7.12E-6
K-562	0.285	2.433	2.349	2.509	0.536	0.215	0.369	96	104	12	-25	4	3.83E-7	.	> 1.00E-4
MOLT-4	0.625	2.476	2.430	2.514	2.129	0.527	0.761	97	102	81	-16	7	2.10E-6	.	> 1.00E-4
RPMI-8226	0.725	2.215	2.150	2.222	1.566	0.486	0.740	96	100	56	-33	1	1.18E-6	.	> 1.00E-4
SR	0.400	1.010	0.984	0.966	0.359	0.253	0.379	96	93	-10	-37	-5	2.60E-7	7.93E-7	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.310	1.921	1.936	1.955	1.203	0.139	0.656	101	102	55	-55	21	1.12E-6	.	.
EKVX	0.678	1.874	1.765	1.804	1.342	0.637	0.902	91	94	56	-6	19	1.23E-6	.	> 1.00E-4
HOP-62	0.665	1.971	1.983	1.983	1.405	0.499	0.349	101	101	57	-25	-48	1.21E-6	4.95E-6	> 1.00E-4
HOP-92	0.960	1.692	1.537	1.542	1.393	0.811	0.713	79	80	59	-16	-26	1.33E-6	6.20E-6	> 1.00E-4
NCI-H226	0.875	2.083	2.037	2.016	1.728	0.724	1.252	96	94	71	-17	31	1.71E-6	.	> 1.00E-4
NCI-H23	0.569	1.947	1.883	1.872	1.383	0.599	0.441	95	95	59	2	-22	1.44E-6	1.22E-5	> 1.00E-4
NCI-H322M	0.808	2.041	1.864	1.918	1.590	0.821	1.241	86	90	63	1	35	1.64E-6	> 1.00E-4	> 1.00E-4
NCI-H460	0.185	1.828	1.835	1.958	0.557	0.081	0.196	100	108	23	-56	1	4.78E-7	.	.
NCI-H522	0.757	2.377	2.215	2.164	1.318	0.531	0.737	90	87	35	-30	-3	5.08E-7	3.44E-6	> 1.00E-4
Colon Cancer															
COLO 205	0.396	1.248	1.170	1.280	0.817	0.197	0.373	91	104	49	-50	-6	9.76E-7	3.13E-6	.
HCC-2998	0.868	2.679	2.639	2.595	2.064	0.454	0.810	98	95	66	-48	-7	1.38E-6	3.81E-6	> 1.00E-4
HCT-116	0.162	1.758	1.720	1.792	0.402	0.042	0.140	98	102	15	-74	-14	3.97E-7	1.47E-6	.
HCT-15	0.291	1.562	1.533	1.502	0.622	0.267	0.438	98	95	26	-8	12	4.51E-7	.	> 1.00E-4
HT29	0.193	1.502	1.519	1.534	0.536	0.108	0.227	101	102	26	-44	3	4.87E-7	.	> 1.00E-4
KM12	0.396	2.090	1.896	1.963	0.782	0.306	0.456	89	93	23	-23	4	4.07E-7	.	> 1.00E-4
SW-620	0.248	1.861	1.821	1.830	0.630	0.266	0.523	98	98	24	1	17	4.43E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.567	2.085	2.004	2.068	1.312	0.432	0.368	95	99	49	-24	-35	9.59E-7	4.71E-6	> 1.00E-4
SF-295	1.110	3.031	2.863	3.079	1.550	0.648	0.619	91	102	23	-42	-44	4.56E-7	2.26E-6	> 1.00E-4
SF-539	1.011	2.322	2.145	2.288	1.122	0.277	0.050	87	97	8	-73	-95	3.41E-7	1.27E-6	5.26E-6
SNB-19	0.635	2.071	1.956	2.021	1.465	0.722	0.269	92	97	58	6	-58	1.41E-6	1.24E-5	7.59E-5
SNB-75	1.546	2.425	2.068	2.092	1.493	0.970	0.465	59	62	-3	-37	-70	1.53E-7	8.87E-7	2.45E-5
U251	0.296	1.624	1.553	1.574	0.670	0.152	0.168	95	96	28	-49	-43	4.77E-7	2.32E-6	> 1.00E-4
Melanoma															
LOX IMVI	0.431	2.841	2.625	2.719	1.566	0.169	0.672	91	95	47	-61	10	8.69E-7	.	.
MALME-3M	0.790	1.760	1.616	1.678	1.199	0.514	0.779	85	92	42	-35	-1	6.95E-7	3.52E-6	> 1.00E-4
M14	0.457	2.039	1.953	2.003	0.893	0.236	0.442	95	98	28	-48	-3	4.79E-7	2.31E-6	> 1.00E-4
MDA-MB-435	0.587	2.534	2.456	2.466	0.317	0.277	0.205	96	96	-46	-53	-65	2.12E-7	4.76E-7	3.80E-6
SK-MEL-2	0.834	2.124	2.028	2.077	1.655	0.545	0.141	93	96	64	-35	-83	1.38E-6	4.44E-6	2.07E-5
SK-MEL-28	0.683	1.861	1.797	1.834	1.243	0.604	0.901	95	98	48	-12	19	8.94E-7	.	> 1.00E-4
SK-MEL-5	0.792	2.702	2.572	2.652	1.286	0.345	0.733	93	97	26	-57	-7	4.59E-7	2.06E-6	.
UACC-257	0.742	1.965	1.947	1.969	1.357	0.451	0.930	99	100	50	-39	15	1.01E-6	.	> 1.00E-4
UACC-62	0.869	2.657	2.600	2.646	1.387	0.664	0.668	97	99	29	-24	-23	5.02E-7	3.55E-6	> 1.00E-4
Ovarian Cancer															
IGROV1	0.811	2.450	2.323	2.298	1.543	0.522	0.578	92	91	45	-36	-29	7.64E-7	3.60E-6	> 1.00E-4
OVCAR-3	0.328	1.228	1.183	1.181	0.474	0.118	0.186	95	95	16	-64	-43	3.71E-7	1.59E-6	.
OVCAR-4	0.653	1.538	1.538	1.513	1.078	0.508	0.637	100	97	48	-22	-2	9.09E-7	4.83E-6	> 1.00E-4
OVCAR-5	0.629	1.273	1.176	1.192	1.006	0.420	0.680	85	87	59	-33	8	1.24E-6	.	> 1.00E-4
OVCAR-8	0.439	1.847	1.939	2.054	1.493	0.144	0.284	107	115	75	-67	-35	1.50E-6	3.36E-6	.
NCI/ADR-RES	0.650	2.030	1.880	1.956	0.842	0.293	0.610	89	95	14	-55	-6	3.57E-7	1.59E-6	.
SK-OV-3	0.776	1.722	1.659	1.718	1.229	0.665	0.463	93	100	48	-14	-40	9.11E-7	5.89E-6	> 1.00E-4
Renal Cancer															
786-0	0.617	2.532	2.379	2.358	1.672	0.410	0.158	92	91	55	-34	-74	1.14E-6	4.18E-6	2.52E-5
A498	1.583	2.284	2.060	2.061	1.405	0.799	0.767	68	68	-11	-50	-52	1.69E-7	7.21E-7	1.70E-5
ACHN	0.297	1.076	1.073	1.066	0.501	0.145	0.156	100	99	26	-51	-48	4.70E-7	2.18E-6	.
CAKI-1	1.018	2.593	2.272	2.300	1.419	0.382	0.917	80	81	25	-63	-10	3.64E-7	1.95E-6	.
RXF 393	1.326	2.011	1.847	1.916	1.476	0.784	0.449	76	86	22	-41	-66	3.65E-7	2.23E-6	2.29E-5
SN12C	0.728	2.666	2.596	2.666	2.080	0.555	1.451	96	100	70	-24	37	1.63E-6	.	> 1.00E-4
TK-10	0.824	2.107	2.005	2.067	1.777	0.668	0.277	92	97	74	-19	-66	1.82E-6	6.26E-6	4.52E-5
UO-31	0.924	2.047	1.871	1.865	1.375	0.199	1.367	84	84	40	-78	39	5.95E-7	.	.
Prostate Cancer															
PC-3	0.455	1.966	1.859	1.767	1.105	0.374	0.675	93	87	43	-18	15	6.93E-7	.	> 1.00E-4
DU-145	0.363	1.603	1.598	1.631	1.187	0.235	0.470	100	102	66	-35	9	1.45E-6	.	> 1.00E-4
Breast Cancer															
MCF7	0.394	1.955	1.673	1.818	0.639	0.311	0.421	82	91	16	-21	2	3.51E-7	.	> 1.00E-4
MDA-MB-231/ATCC	0.745	1.458	1.406	1.474	1.217	0.379	0.540	93	102	66	-49	-28	1.38E-6	3.74E-6	> 1.00E-4
HS 578T	0.921	1.940	1.898	1.971	1.262	0.807	0.839	96	103	33	-12	-9	5.78E-7	5.36E-6	> 1.00E-4
BT-549	1.385	2.748	2.633	2.594	2.300	1.350	1.186	92	89	67	-3	-14	1.76E-6	9.19E-6	> 1.00E-4
T-47D	0.652	1.376	1.245	1.269	0.792	0.561	0.771	82	85	19	-14	16	3.43E-7	.	> 1.00E-4
MDA-MB-468	0.819	1.817	1.706	1.759	0.917	0.651	0.650	89	94	10	-21	-21	3.34E-7	2.11E-6	> 1.00E-4



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 809877 / 1

Experiment ID : 1812NS43

Test Type : 08

Report Date : January 09, 2019


Test Date : December 17, 2018

QNS :










COMI : IA-643

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration					Percent Growth					GI50	TGI	LC50
			-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.328	1.604	1.560	1.609	0.556	0.357	0.366	97	100	18	2	3	4.08E-7	> 1.00E-4	> 1.00E-4
HL-60(TB)	1.047	3.435	3.364	3.418	0.941	0.485	0.493	97	99	-10	-54	-53	2.82E-7	8.07E-7	8.21E-6
K-562	0.285	2.473	2.496	2.535	0.628	0.365	0.489	101	103	16	4	9	4.04E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.625	2.678	2.691	2.785	1.656	0.761	1.112	101	105	50	7	24	1.01E-6	> 1.00E-4	> 1.00E-4
RPMI-8226	0.725	2.159	2.016	2.073	1.055	0.655	0.866	90	94	23	-10	10	4.17E-7	.	> 1.00E-4
SR	0.400	1.174	1.154	1.102	0.456	0.363	0.454	97	91	7	-9	7	3.07E-7	.	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.310	1.875	1.951	1.898	1.070	0.495	0.580	105	101	49	12	17	9.38E-7	> 1.00E-4	> 1.00E-4
EKVX	0.678	1.900	1.841	1.843	1.439	1.025	1.007	95	95	62	28	27	2.30E-6	> 1.00E-4	> 1.00E-4
HOP-62	0.665	2.025	1.933	1.906	1.126	0.815	0.291	93	91	34	11	-56	5.24E-7	1.46E-5	8.06E-5
HOP-92	0.960	1.644	1.486	1.482	1.345	1.125	0.814	77	76	56	24	-15	1.57E-6	4.11E-5	> 1.00E-4
NCI-H226	0.875	2.161	2.098	2.093	1.805	1.295	1.334	95	95	72	33	36	3.65E-6	> 1.00E-4	> 1.00E-4
NCI-H23	0.569	1.907	1.812	1.877	1.457	0.778	0.612	93	98	66	16	3	2.10E-6	> 1.00E-4	> 1.00E-4
NCI-H322M	0.808	2.050	1.943	1.946	1.670	1.286	1.254	91	92	69	38	36	4.23E-6	> 1.00E-4	> 1.00E-4
NCI-H460	0.185	1.832	1.775	1.894	0.654	0.219	0.235	97	104	28	2	3	5.18E-7	> 1.00E-4	> 1.00E-4
NCI-H522	0.757	2.345	2.158	2.177	1.038	0.516	0.592	88	89	18	-32	-22	3.54E-7	2.28E-6	> 1.00E-4
Colon Cancer															
COLO 205	0.396	1.309	1.235	1.244	0.595	0.247	0.298	92	93	22	-38	-25	4.01E-7	2.32E-6	> 1.00E-4
HCC-2998	0.868	2.666	2.553	2.568	2.228	1.080	0.945	94	95	76	12	4	2.52E-6	> 1.00E-4	> 1.00E-4
HCT-116	0.162	1.735	1.646	1.757	0.495	0.225	0.251	94	101	21	4	6	4.37E-7	> 1.00E-4	> 1.00E-4
HCT-15	0.291	1.665	1.547	1.628	0.689	0.514	0.571	91	97	29	16	20	4.92E-7	> 1.00E-4	> 1.00E-4
HT29	0.193	1.500	1.491	1.540	0.303	0.192	0.203	99	103	8	.	1	3.64E-7	.	> 1.00E-4
KM12	0.396	2.031	1.847	1.814	0.784	0.536	0.575	89	87	24	9	11	3.83E-7	> 1.00E-4	> 1.00E-4
SW-620	0.248	1.912	1.863	1.889	0.716	0.678	0.604	97	99	28	26	21	4.89E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.567	2.044	1.942	1.996	1.198	0.812	0.492	93	97	43	17	-13	7.33E-7	3.59E-5	> 1.00E-4
SF-295	1.110	2.948	2.871	3.008	1.780	1.141	0.648	96	103	36	2	-42	6.27E-7	1.09E-5	> 1.00E-4
SF-539	1.011	2.470	2.345	2.346	1.161	0.664	0.364	91	92	10	-34	-64	3.24E-7	1.70E-6	3.37E-5
SNB-19	0.635	2.061	1.967	2.054	1.536	1.035	0.427	93	100	63	28	-33	2.38E-6	2.89E-5	> 1.00E-4
SNB-75	1.546	2.370	2.088	2.224	1.459	1.167	0.622	66	82	-6	-25	-60	2.33E-7	8.62E-7	5.28E-5
U251	0.296	1.591	1.525	1.514	0.635	0.429	0.263	95	94	26	10	-11	4.45E-7	2.99E-5	> 1.00E-4
Melanoma															
LOX IMVI	0.431	2.778	2.626	2.693	1.574	0.804	0.826	94	96	49	16	17	9.38E-7	> 1.00E-4	> 1.00E-4
MALME-3M	0.790	1.704	1.569	1.629	1.228	1.120	0.813	85	92	48	36	2	8.97E-7	> 1.00E-4	> 1.00E-4
M14	0.457	1.970	1.933	1.984	0.813	0.613	0.489	98	101	24	10	2	4.55E-7	> 1.00E-4	> 1.00E-4
MDA-MB-435	0.587	2.535	2.498	2.508	0.360	0.459	0.208	98	99	-39	-22	-65	2.26E-7	5.22E-7	4.56E-5
SK-MEL-2	0.834	2.111	2.039	2.085	1.423	0.945	0.389	94	98	46	9	-53	8.42E-7	1.38E-5	8.83E-5
SK-MEL-28	0.683	2.017	1.935	1.995	1.379	1.123	1.020	94	98	52	33	25	1.30E-6	> 1.00E-4	> 1.00E-4
SK-MEL-5	0.792	2.645	2.540	2.597	1.383	0.736	0.998	94	97	32	-7	11	5.29E-7	.	> 1.00E-4
UACC-257	0.742	2.071	2.059	2.116	1.429	1.238	1.382	99	103	52	37	48	1.31E-6	> 1.00E-4	> 1.00E-4
UACC-62	0.869	2.682	2.605	2.634	1.466	1.208	0.819	96	97	33	19	-6	5.43E-7	5.82E-5	> 1.00E-4
Ovarian Cancer															
IGROV1	0.811	2.458	2.344	2.389	1.688	0.973	0.729	93	96	53	10	-10	1.19E-6	3.11E-5	> 1.00E-4
OVCAR-3	0.328	1.122	1.081	1.110	0.252	0.168	0.118	95	99	-23	-49	-64	2.50E-7	6.45E-7	1.20E-5
OVCAR-4	0.653	1.531	1.525	1.548	1.064	0.895	0.953	99	102	47	28	34	8.73E-7	> 1.00E-4	> 1.00E-4
OVCAR-5	0.629	1.388	1.340	1.350	1.123	0.833	0.880	94	95	65	27	33	2.48E-6	> 1.00E-4	> 1.00E-4
OVCAR-8	0.439	1.908	1.901	1.941	1.019	0.480	0.559	99	102	39	3	8	6.79E-7	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.650	2.048	1.905	1.958	1.113	0.643	0.604	90	94	33	-1	-7	5.26E-7	9.25E-6	> 1.00E-4
SK-OV-3	0.776	1.811	1.750	1.750	1.092	0.905	0.712	94	94	30	12	-8	4.93E-7	3.98E-5	> 1.00E-4
Renal Cancer															
786-0	0.617	2.461	2.244	2.337	1.500	1.203	0.254	88	93	48	32	-59	8.98E-7	2.24E-5	7.99E-5
A498	1.583	2.267	2.139	2.196	1.594	1.215	1.277	81	90	2	-23	-19	2.82E-7	1.15E-6	> 1.00E-4
ACHN	0.297	1.153	1.108	1.157	0.631	0.452	0.175	95	100	39	18	-41	6.62E-7	2.02E-5	> 1.00E-4
CAKI-1	1.018	2.560	2.348	2.430	1.482	1.319	1.124	86	92	30	20	7	4.74E-7	> 1.00E-4	> 1.00E-4
RXF 393	1.326	1.970	1.791	1.871	1.481	1.238	0.901	72	85	24	-7	-32	3.72E-7	6.06E-6	> 1.00E-4
SN12C	0.728	2.651	2.500	2.614	2.136	0.986	1.356	92	98	73	13	33	2.44E-6	> 1.00E-4	> 1.00E-4
TK-10	0.824	2.070	2.009	2.068	1.642	1.325	0.501	95	100	66	40	-39	4.12E-6	3.20E-5	> 1.00E-4
UO-31	0.924	2.047	1.885	1.939	1.498	1.230	1.396	86	90	51	27	42	1.11E-6	> 1.00E-4	> 1.00E-4
Prostate Cancer															
PC-3	0.455	1.892	1.853	1.814	1.000	0.672	0.789	97	95	38	15	23	6.12E-7	> 1.00E-4	> 1.00E-4
DU-145	0.363	1.507	1.492	1.491	0.897	0.357	0.356	99	99	47	-2	-2	8.64E-7	9.24E-6	> 1.00E-4
Breast Cancer															
MCF7	0.394	1.963	1.850	1.932	0.793	0.624	0.820	93	98	25	15	27	4.58E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.745	1.472	1.469	1.514	1.298	0.728	0.711	100	106	76	-2	-5	2.15E-6	9.35E-6	> 1.00E-4
HS 578T	0.921	1.975	1.897	2.011	1.398	0.950	0.827	93	103	45	3	-10	8.29E-7	1.63E-5	> 1.00E-4
BT-549	1.385	2.682	2.588	2.588	2.301	1.612	1.568	93	93	71	18	14	2.45E-6	> 1.00E-4	> 1.00E-4
T-47D	0.652	1.381	1.323	1.216	0.812	0.818	0.882	92	77	22	23	31	3.11E-7	> 1.00E-4	> 1.00E-4
MDA-MB-468	0.819	1.815	1.705	1.730	0.875	0.797	0.577	89	91	6	-3	-30	3.04E-7	4.75E-6	> 1.00E-4



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 809883 / 1

Experiment ID : 1812NS43

Test Type : 08

Report Date : January 09, 2019


Test Date : December 17, 2018

QNS :










COMI : MM-195

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration										GI50	TGI	LC50
			Mean Optical Densities					Percent Growth							
			-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.328	1.814	1.813	1.795	1.647	0.310	0.469	100	99	89	-5	9	2.58E-6	.	> 1.00E-4
HL-60(TB)	1.047	3.394	3.313	3.346	3.229	0.424	0.451	97	98	93	-60	-57	1.91E-6	4.07E-6	8.66E-6
K-562	0.285	2.557	2.601	2.575	0.906	0.205	0.398	102	101	27	-28	5	4.91E-7	.	> 1.00E-4
MOLT-4	0.625	2.682	2.630	2.677	2.479	0.557	0.838	97	100	90	-11	10	2.50E-6	.	> 1.00E-4
RPMI-8226	0.725	2.297	2.134	2.316	2.079	0.600	0.911	90	101	86	-17	12	2.24E-6	.	> 1.00E-4
SR	0.400	1.132	1.061	1.116	0.544	0.269	0.424	90	98	20	-33	3	4.09E-7	.	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.310	1.821	1.711	1.775	1.447	0.050	0.433	93	97	75	-84	8	1.44E-6	.	.
EKVX	0.678	1.954	1.887	1.879	1.647	0.611	0.999	95	94	76	-10	25	2.00E-6	.	> 1.00E-4
HOP-62	0.665	1.923	1.932	1.906	1.651	0.293	0.164	101	99	78	-56	-75	1.62E-6	3.83E-6	9.02E-6
HOP-92	0.960	1.724	1.554	1.585	1.411	0.535	0.672	78	82	59	-44	-30	1.22E-6	3.72E-6	> 1.00E-4
NCI-H226	0.875	2.102	2.042	2.096	1.876	0.595	1.183	95	99	82	-32	25	1.90E-6	.	> 1.00E-4
NCI-H23	0.569	1.895	1.822	1.848	1.614	0.394	0.213	95	96	79	-31	-63	1.83E-6	5.23E-6	4.02E-5
NCI-H322M	0.808	2.076	1.951	1.957	1.887	0.500	1.232	90	91	85	-38	33	1.93E-6	.	> 1.00E-4
NCI-H460	0.185	1.821	1.868	1.917	1.550	0.053	0.137	103	106	83	-71	-26	1.64E-6	3.46E-6	.
NCI-H522	0.757	2.260	2.039	2.081	1.429	0.156	0.157	85	88	45	-79	-79	7.54E-7	2.29E-6	5.80E-6
Colon Cancer															
COLO 205	0.396	1.219	1.167	1.181	1.026	0.150	0.195	94	95	77	-62	-51	1.55E-6	3.56E-6	8.16E-6
HCC-2998	0.868	2.689	2.546	2.643	2.524	0.237	0.714	92	97	91	-73	-18	1.78E-6	3.59E-6	.
HCT-116	0.162	1.787	1.747	1.810	1.357	0.029	0.095	98	101	74	-82	-41	1.42E-6	2.97E-6	.
HCT-15	0.291	1.574	1.442	1.502	0.952	0.234	0.374	90	94	51	-20	6	1.05E-6	.	> 1.00E-4
HT29	0.193	1.425	1.396	1.431	1.315	0.003	0.081	98	100	91	-98	-58	1.65E-6	3.02E-6	5.55E-6
KM12	0.396	1.907	1.775	1.787	1.156	0.076	0.335	91	92	50	-81	-15	1.01E-6	2.42E-6	.
SW-620	0.248	1.812	1.727	1.794	1.128	0.137	0.496	95	99	56	-45	16	1.15E-6	.	> 1.00E-4
CNS Cancer															
SF-268	0.567	2.023	1.925	1.984	1.606	0.270	0.269	93	97	71	-52	-53	1.49E-6	3.77E-6	9.57E-6
SF-295	1.110	2.969	2.818	2.982	1.958	0.617	0.335	92	101	46	-44	-70	8.33E-7	3.21E-6	1.65E-5
SF-539	1.011	2.477	2.332	2.298	2.026	0.031	0.004	90	88	69	-97	-100	1.30E-6	2.61E-6	5.22E-6
SNB-19	0.635	2.168	2.056	2.128	1.876	0.435	0.328	93	97	81	-31	-48	1.88E-6	5.25E-6	> 1.00E-4
SNB-75	1.546	2.366	2.066	2.180	1.641	0.430	0.445	63	77	12	-72	-71	2.60E-7	1.37E-6	5.43E-6
U251	0.296	1.570	1.535	1.461	1.172	0.031	0.098	97	91	69	-90	-67	1.31E-6	2.72E-6	5.62E-6
Melanoma															
LOX IMVI	0.431	2.941	2.732	2.774	2.308	0.131	0.427	92	93	75	-70	-1	1.48E-6	3.29E-6	.
MALME-3M	0.790	1.824	1.626	1.669	1.412	0.467	1.008	81	85	60	-41	21	1.26E-6	.	> 1.00E-4
M14	0.457	2.097	2.039	2.070	1.459	0.271	0.379	96	98	61	-41	-17	1.28E-6	3.98E-6	> 1.00E-4
MDA-MB-435	0.587	2.489	2.406	2.462	0.633	0.171	0.131	96	99	2	-71	-78	3.20E-7	1.08E-6	5.18E-6
SK-MEL-2	0.834	1.971	1.882	1.933	1.729	0.223	0.068	92	97	79	-73	-92	1.55E-6	3.29E-6	7.02E-6
SK-MEL-28	0.683	2.003	1.890	2.022	1.470	0.601	0.794	91	101	60	-12	8	1.36E-6	.	> 1.00E-4
SK-MEL-5	0.792	2.648	2.555	2.602	2.131	0.229	0.465	95	98	72	-71	-41	1.43E-6	3.19E-6	.
UACC-257	0.742	1.949	1.836	1.935	1.472	0.686	1.220	91	99	60	-8	40	1.43E-6	.	> 1.00E-4
UACC-62	0.869	2.821	2.726	2.743	1.894	0.443	0.364	95	96	53	-49	-58	1.06E-6	3.29E-6	1.28E-5
Ovarian Cancer															
IGROV1	0.811	2.513	2.338	2.359	2.123	0.424	0.475	90	91	77	-48	-41	1.65E-6	4.15E-6	> 1.00E-4
OVCAR-3	0.328	1.187	1.164	1.155	0.950	0.070	0.079	97	96	72	-79	-76	1.41E-6	3.01E-6	6.45E-6
OVCAR-4	0.653	1.491	1.500	1.465	1.234	0.269	0.921	101	97	69	-59	32	1.42E-6	.	.
OVCAR-5	0.629	1.380	1.280	1.319	1.215	0.276	0.713	87	92	78	-56	11	1.62E-6	.	.
OVCAR-8	0.439	1.782	1.807	1.824	1.758	0.084	0.265	102	103	98	-81	-40	1.86E-6	3.53E-6	.
NCI/ADR-RES	0.650	2.031	1.916	1.925	1.343	0.277	0.439	92	92	50	-57	-33	1.00E-6	2.93E-6	.
SK-OV-3	0.776	1.708	1.613	1.681	1.485	0.100	0.287	90	97	76	-87	-63	1.44E-6	2.92E-6	5.92E-6
Renal Cancer															
786-0	0.617	2.554	2.362	2.397	2.213	0.137	0.101	90	92	82	-78	-84	1.59E-6	3.27E-6	6.71E-6
A498	1.583	2.267	2.117	2.084	1.721	0.476	0.445	78	73	20	-70	-72	2.74E-7	1.67E-6	6.01E-6
ACHN	0.297	1.120	1.087	1.150	0.792	0.041	0.095	96	104	60	-86	-68	1.17E-6	2.57E-6	5.66E-6
CAKI-1	1.018	2.674	2.416	2.432	1.579	0.253	0.533	84	85	34	-75	-48	4.87E-7	2.04E-6	.
RXF 393	1.326	1.974	1.794	1.881	1.625	0.585	0.306	72	86	46	-56	-77	7.98E-7	2.83E-6	8.76E-6
SN12C	0.728	2.791	2.659	2.730	2.483	0.348	0.786	94	97	85	-52	3	1.80E-6	.	.
TK-10	0.824	1.954	1.875	1.926	1.901	0.147	0.062	93	97	95	-82	-92	1.80E-6	3.44E-6	6.59E-6
UO-31	0.924	2.124	1.871	1.900	1.580	0.115	0.994	79	81	55	-88	6	1.08E-6	.	.
Prostate Cancer															
PC-3	0.455	1.955	1.858	1.841	1.486	0.334	0.812	93	92	69	-27	24	1.57E-6	.	> 1.00E-4
DU-145	0.363	1.609	1.558	1.589	1.522	0.185	0.237	96	98	93	-49	-35	2.01E-6	4.52E-6	> 1.00E-4
Breast Cancer															
MCF7	0.394	1.980	1.701	1.822	0.715	0.347	0.719	82	90	20	-12	20	3.75E-7	.	> 1.00E-4
MDA-MB-231/ATCC	0.745	1.705	1.673	1.686	1.581	0.377	0.337	97	98	87	-49	-55	1.87E-6	4.34E-6	1.26E-5
HS 578T	0.921	1.903	1.818	1.847	1.421	0.671	0.787	91	94	51	-27	-15	1.03E-6	4.48E-6	> 1.00E-4
BT-549	1.385	2.760	2.654	2.663	2.488	1.401	0.860	92	93	80	1	-38	2.41E-6	1.07E-5	> 1.00E-4
T-47D	0.652	1.352	1.241	1.273	1.178	0.442	0.824	84	89	75	-32	25	1.71E-6	.	> 1.00E-4
MDA-MB-468	0.819	1.791	1.727	1.756	0.961	0.542	0.403	93	96	15	-34	-51	3.69E-7	2.00E-6	8.91E-6



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 809878 / 1

Experiment ID : 1901NS49

Test Type : 08

Report Date : January 28, 2019


Test Date : January 07, 2019

QNS :










COMI : IA-662

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration										GI50	TGI	LC50
			Mean Optical Densities					Percent Growth							
			-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.444	2.440	2.299	2.350	2.155	0.475	0.580	93	95	86	2	7	2.66E-6	> 1.00E-4	> 1.00E-4
HL-60(TB)	1.381	3.412	3.427	3.449	3.413	0.648	0.507	101	102	100	-53	-63	2.12E-6	4.50E-6	9.55E-6
K-562	0.228	2.340	2.183	2.226	0.999	0.306	0.405	93	95	37	4	8	5.86E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.414	2.167	2.031	2.158	1.986	0.463	0.608	92	100	90	3	11	2.86E-6	> 1.00E-4	> 1.00E-4
RPMI-8226	0.620	1.698	1.593	1.687	1.387	0.482	0.452	90	99	71	-22	-27	1.68E-6	5.77E-6	> 1.00E-4
SR	0.192	0.771	0.658	0.679	0.380	0.258	0.240	80	84	32	11	8	4.56E-7	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.360	2.354	2.225	2.191	1.916	0.194	0.473	94	92	78	-46	6	1.68E-6	.	> 1.00E-4
EKVX	1.002	1.915	1.786	1.839	1.501	1.163	1.074	86	92	55	18	8	1.34E-6	> 1.00E-4	> 1.00E-4
HOP-62	0.516	2.164	1.993	2.104	1.766	0.424	0.387	90	96	76	-18	-25	1.89E-6	6.45E-6	> 1.00E-4
HOP-92	1.350	2.221	2.072	2.117	1.909	1.085	1.097	83	88	64	-20	-19	1.47E-6	5.83E-6	> 1.00E-4
NCI-H226	1.196	2.711	2.690	2.756	2.583	1.055	1.179	99	103	92	-12	-1	2.52E-6	7.69E-6	> 1.00E-4
NCI-H23	0.672	2.181	2.131	2.165	1.883	0.481	0.072	97	99	80	-28	-89	1.90E-6	5.47E-6	2.26E-5
NCI-H460	0.338	3.150	3.174	3.186	2.673	0.141	0.179	101	101	83	-58	-47	1.71E-6	3.87E-6	.
NCI-H522	1.100	2.924	2.718	2.707	2.020	0.762	0.875	89	88	50	-31	-20	1.01E-6	4.18E-6	> 1.00E-4
Colon Cancer															
COLO 205	0.502	2.265	2.174	2.146	2.011	0.304	0.608	95	93	86	-40	6	1.92E-6	.	> 1.00E-4
HCC-2998	0.842	2.727	2.565	2.684	2.501	0.456	0.513	91	98	88	-46	-39	1.92E-6	4.54E-6	> 1.00E-4
HCT-116	0.251	2.383	2.272	2.294	1.388	0.048	0.078	95	96	53	-81	-69	1.06E-6	2.49E-6	5.87E-6
HCT-15	0.334	1.892	1.818	1.859	1.313	0.178	0.162	95	98	63	-47	-51	1.31E-6	3.75E-6	4.87E-5
HT29	0.320	2.240	2.127	2.178	1.629	0.196	0.406	94	97	68	-39	4	1.48E-6	.	> 1.00E-4
KM12	0.516	2.690	2.643	2.644	1.326	0.562	0.335	98	98	37	2	-35	6.16E-7	1.14E-5	> 1.00E-4
SW-620	0.281	1.735	1.696	1.676	1.033	0.311	0.510	97	96	52	2	16	1.08E-6	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.687	2.178	2.063	2.077	1.820	0.954	0.416	92	93	76	18	-39	2.80E-6	2.05E-5	> 1.00E-4
SF-295	1.317	3.253	3.176	3.199	2.550	0.725	0.300	96	97	64	-45	-77	1.34E-6	3.86E-6	1.43E-5
SF-539	0.617	2.178	2.059	2.099	1.504	0.056	0.086	92	95	57	-91	-86	1.11E-6	2.42E-6	5.28E-6
SNB-19	0.538	1.948	1.873	1.931	1.631	0.603	0.155	95	99	78	5	-71	2.39E-6	1.15E-5	5.25E-5
SNB-75	0.781	1.405	1.242	1.308	1.070	0.234	0.202	74	85	46	-70	-74	8.02E-7	2.50E-6	6.72E-6
U251	0.426	2.251	2.087	2.096	1.689	0.424	0.338	91	91	69	.	-21	1.88E-6	9.81E-6	> 1.00E-4
Melanoma															
LOX IMVI	0.405	2.910	2.808	2.842	1.670	0.071	0.424	96	97	50	-83	1	1.01E-6	.	.
MALME-3M	0.645	1.467	1.319	1.362	1.127	0.420	0.885	82	87	59	-35	29	1.24E-6	.	> 1.00E-4
M14	0.499	2.006	1.877	1.904	1.453	0.239	0.416	91	93	63	-52	-17	1.30E-6	3.54E-6	.
MDA-MB-435	0.524	2.466	2.302	2.337	0.614	0.114	0.072	92	93	5	-78	-86	3.08E-7	1.14E-6	4.55E-6
SK-MEL-2	1.162	2.853	2.706	2.732	2.461	1.219	0.506	91	93	77	3	-56	2.32E-6	1.14E-5	7.79E-5
SK-MEL-28	1.019	2.974	2.862	2.905	2.419	1.394	1.595	94	96	72	19	29	2.58E-6	> 1.00E-4	> 1.00E-4
SK-MEL-5	1.441	3.313	3.308	3.327	2.895	0.459	0.188	100	101	78	-68	-87	1.55E-6	3.41E-6	7.50E-6
UACC-257	0.875	2.433	2.211	2.317	1.833	1.520	1.553	86	93	61	41	43	3.72E-6	> 1.00E-4	> 1.00E-4
UACC-62	0.793	2.867	2.783	2.818	1.557	0.763	0.519	96	98	37	-4	-35	6.07E-7	8.04E-6	> 1.00E-4
Ovarian Cancer															
IGROV1	0.444	2.117	1.949	2.019	1.382	0.390	0.388	90	94	56	-12	-13	1.23E-6	6.63E-6	> 1.00E-4
OVCAR-3	0.511	1.928	1.868	1.865	1.658	0.275	0.107	96	96	81	-46	-79	1.75E-6	4.33E-6	1.31E-5
OVCAR-4	0.559	1.638	1.605	1.637	1.103	0.724	0.742	97	100	50	15	17	1.02E-6	> 1.00E-4	> 1.00E-4
OVCAR-5	0.498	1.633	1.516	1.493	1.387	0.467	0.879	90	88	78	-6	34	2.16E-6	.	> 1.00E-4
OVCAR-8	0.405	2.298	2.197	2.219	2.051	0.268	0.550	95	96	87	-34	8	2.02E-6	.	> 1.00E-4
NCI/ADR-RES	0.582	1.949	1.888	1.915	1.632	0.233	0.423	96	97	77	-60	-27	1.57E-6	3.64E-6	.
SK-OV-3	1.014	2.373	2.274	2.290	2.062	1.147	0.724	93	94	77	10	-29	2.53E-6	1.80E-5	> 1.00E-4
Renal Cancer															
786-O	0.715	2.795	2.714	2.733	2.457	0.398	0.257	96	97	84	-44	-64	1.83E-6	4.50E-6	1.92E-5
A498	1.390	2.319	2.175	2.306	1.641	0.856	0.494	84	99	27	-38	-64	4.77E-7	2.59E-6	2.78E-5
ACHN	0.339	1.633	1.516	1.534	1.299	0.286	0.331	91	92	74	-16	-2	1.86E-6	6.70E-6	> 1.00E-4
CAKI-1	0.641	2.338	2.205	2.157	1.359	0.475	0.203	92	89	42	-26	-68	6.86E-7	4.17E-6	3.69E-5
RXF 393	0.945	1.609	1.553	1.564	1.234	0.621	0.225	92	93	43	-34	-76	7.38E-7	3.62E-6	2.37E-5
SN12C	0.803	3.007	2.915	2.935	2.748	0.497	0.609	96	97	88	-38	-24	2.01E-6	4.99E-6	> 1.00E-4
TK-10	0.937	2.448	2.301	2.391	2.297	1.677	0.860	90	96	90	49	-8	9.44E-6	7.17E-5	> 1.00E-4
UO-31	0.865	2.190	2.001	2.007	1.704	0.312	0.892	86	86	63	-64	2	1.27E-6	.	.
Prostate Cancer															
PC-3	0.635	2.623	2.472	2.534	2.296	0.861	1.041	92	96	84	11	20	2.91E-6	> 1.00E-4	> 1.00E-4
DU-145	0.502	2.044	1.999	2.057	1.980	0.487	0.162	97	101	96	-3	-68	2.91E-6	9.33E-6	5.32E-5
Breast Cancer															
MCF7	0.610	2.851	2.699	2.789	1.068	0.722	0.592	93	97	20	5	-3	4.12E-7	4.19E-5	> 1.00E-4
MDA-MB-231/ATCC	0.492	1.253	1.190	1.232	1.139	0.128	0.138	92	97	85	-74	-72	1.66E-6	3.42E-6	7.06E-6
HS 578T	0.992	2.077	1.925	1.934	1.562	0.755	0.785	86	87	52	-24	-21	1.08E-6	4.87E-6	> 1.00E-4
BT-549	1.005	2.069	1.932	1.960	1.841	0.809	0.857	87	90	79	-20	-15	1.96E-6	6.33E-6	> 1.00E-4
T-47D	0.921	2.462	2.220	2.285	1.537	1.727	1.574	84	89	40	52	42	.	> 1.00E-4	> 1.00E-4
MDA-MB-468	0.867	1.801	1.802	1.855	0.714	0.640	0.275	100	106	-18	-26	-68	2.83E-7	7.20E-7	3.67E-5



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 819764 / 1

Experiment ID : 1912NS94

Test Type : 08

Report Date : January 26, 2020


Test Date : December 09, 2019

QNS :










COMI : IA-866

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration										GI50	TGI	LC50
			Mean Optical Densities					Percent Growth							
			-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.432	2.709	2.712	2.767	2.683	0.693	0.471	100	103	99	11	2	3.62E-6	> 1.00E-4	> 1.00E-4
HL-60(TB)	1.123	3.456	3.483	3.489	3.477	1.422	0.862	101	101	101	13	-23	3.78E-6	2.26E-5	> 1.00E-4
K-562	0.188	1.784	1.747	1.668	1.174	0.314	0.157	98	93	62	8	-17	1.65E-6	2.09E-5	> 1.00E-4
MOLT-4	0.541	2.599	2.676	2.598	2.552	0.854	0.488	104	100	98	15	-10	3.79E-6	4.03E-5	> 1.00E-4
SR	0.251	1.293	1.248	1.204	0.712	0.336	0.239	96	92	44	8	-5	7.55E-7	4.17E-5	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.437	2.370	2.305	2.301	2.296	0.898	0.356	97	96	96	24	-19	4.35E-6	3.64E-5	> 1.00E-4
EKVX	0.661	2.028	1.967	1.882	1.840	1.138	0.578	96	89	86	35	-13	5.07E-6	5.42E-5	> 1.00E-4
HOP-62	0.596	2.085	2.118	2.105	2.003	1.046	0.273	102	101	95	30	-54	4.93E-6	2.28E-5	8.92E-5
HOP-92	1.358	2.096	2.038	2.017	1.886	1.498	0.360	92	89	71	19	-73	2.56E-6	1.60E-5	5.57E-5
NCI-H226	1.411	3.042	3.023	3.019	3.003	1.976	0.811	99	99	98	35	-43	5.71E-6	2.81E-5	> 1.00E-4
NCI-H23	0.558	1.919	1.807	1.857	1.813	0.730	0.190	92	95	92	13	-66	3.39E-6	1.45E-5	6.27E-5
NCI-H322M	0.916	2.261	2.171	2.106	2.043	1.699	0.659	93	88	84	58	-28	1.25E-5	4.73E-5	> 1.00E-4
NCI-H460	0.326	2.853	2.872	2.861	2.816	0.502	0.169	101	100	99	7	-48	3.39E-6	1.34E-5	> 1.00E-4
NCI-H522	1.295	3.056	2.996	2.935	2.695	1.663	0.557	97	93	79	21	-57	3.19E-6	1.85E-5	8.12E-5
Colon Cancer															
COLO 205	0.508	2.538	2.529	2.502	2.491	0.630	0.306	100	98	98	6	-40	3.31E-6	1.35E-5	> 1.00E-4
HCC-2998	0.734	2.585	2.526	2.458	2.448	0.964	0.178	97	93	93	12	-76	3.40E-6	1.38E-5	5.10E-5
HCT-116	0.308	2.679	2.664	2.671	2.536	0.590	0.116	99	100	94	12	-63	3.43E-6	1.45E-5	6.79E-5
HCT-15	0.314	1.906	1.884	1.788	1.704	0.561	0.179	99	93	87	16	-43	3.31E-6	1.84E-5	> 1.00E-4
HT29	0.426	2.505	2.559	2.486	2.452	0.680	0.253	103	99	97	12	-41	3.60E-6	1.70E-5	> 1.00E-4
KM12	0.765	3.221	3.166	3.215	2.967	1.243	0.353	98	100	90	19	-54	3.67E-6	1.84E-5	8.86E-5
SW-620	0.351	2.649	2.648	2.602	2.377	1.081	0.136	100	98	88	32	-61	4.75E-6	2.19E-5	7.55E-5
CNS Cancer															
SF-268	0.855	2.617	2.505	2.469	2.254	1.493	0.554	94	92	79	36	-35	4.80E-6	3.21E-5	> 1.00E-4
SF-295	0.680	3.036	2.937	2.850	2.671	0.876	0.179	96	92	84	8	-74	2.84E-6	1.26E-5	5.14E-5
SF-539	0.721	2.722	2.607	2.551	2.541	0.798	0.125	94	91	91	4	-83	2.95E-6	1.11E-5	4.19E-5
SNB-19	0.458	1.587	1.573	1.567	1.554	0.679	0.110	99	98	97	20	-76	4.05E-6	1.60E-5	5.35E-5
SNB-75	1.401	2.429	2.235	2.230	2.141	1.630	0.901	81	81	72	22	-36	2.77E-6	2.42E-5	> 1.00E-4
U251	0.520	2.445	2.412	2.374	2.315	0.964	0.257	98	96	93	23	-51	4.13E-6	2.06E-5	9.82E-5
Melanoma															
LOX IMVI	0.410	2.776	2.643	2.648	2.511	0.776	0.135	94	95	89	15	-67	3.38E-6	1.54E-5	6.19E-5
MALME-3M	0.681	1.503	1.469	1.430	1.372	1.093	0.184	96	91	84	50	-73	1.00E-5	2.55E-5	6.50E-5
M14	0.377	1.760	1.733	1.709	1.639	0.638	0.224	98	96	91	19	-41	3.72E-6	2.07E-5	> 1.00E-4
MDA-MB-435	0.682	2.998	2.948	2.984	2.170	0.606	0.181	98	99	64	-11	-74	1.54E-6	7.10E-6	4.19E-5
SK-MEL-2	1.121	2.133	2.193	2.116	2.140	1.684	0.545	106	98	101	56	-51	1.13E-5	3.31E-5	9.71E-5
SK-MEL-28	0.579	1.920	1.893	1.918	1.697	1.165	0.092	98	100	83	44	-84	6.94E-6	2.20E-5	5.41E-5
SK-MEL-5	0.916	3.155	3.075	3.084	2.961	0.585	0.104	96	97	91	-36	-89	2.11E-6	5.21E-6	1.84E-5
UACC-257	1.066	2.615	2.554	2.568	2.377	2.038	0.580	96	97	85	63	-46	1.31E-5	3.79E-5	> 1.00E-4
UACC-62	0.921	2.766	2.718	2.641	2.337	1.322	0.115	97	93	77	22	-88	3.06E-6	1.58E-5	4.54E-5
Ovarian Cancer															
IGROV1	0.523	2.081	2.089	2.051	1.939	0.863	0.331	101	98	91	22	-37	3.91E-6	2.36E-5	> 1.00E-4
OVCAR-3	0.372	1.316	1.341	1.306	1.265	0.426	0.136	103	99	95	6	-64	3.17E-6	1.21E-5	6.37E-5
OVCAR-4	0.882	1.596	1.642	1.617	1.606	1.194	0.800	106	103	101	44	-9	7.77E-6	6.66E-5	> 1.00E-4
OVCAR-5	0.583	1.460	1.388	1.354	1.320	0.943	0.097	92	88	84	41	-83	6.18E-6	2.14E-5	5.39E-5
OVCAR-8	0.451	2.213	2.162	2.161	2.137	0.934	0.463	97	97	96	27	1	4.67E-6	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.510	1.817	1.816	1.802	1.594	0.562	0.368	100	99	83	4	-28	2.61E-6	1.33E-5	> 1.00E-4
SK-OV-3	0.657	1.730	1.725	1.659	1.688	1.211	0.608	100	93	96	52	-8	1.07E-5	7.46E-5	> 1.00E-4
Renal Cancer															
786-O	0.812	2.885	2.882	2.809	2.780	1.542	0.454	100	96	95	35	-44	5.65E-6	2.78E-5	> 1.00E-4
A498	1.592	2.145	2.008	2.071	1.890	1.199	0.149	75	87	54	-25	-91	1.12E-6	4.85E-6	2.42E-5
ACHN	0.410	1.732	1.688	1.666	1.607	0.723	0.132	97	95	90	24	-68	4.04E-6	1.81E-5	6.37E-5
CAKI-1	0.652	2.204	2.036	1.982	1.526	1.156	0.254	89	86	56	32	-61	1.84E-6	2.22E-5	7.62E-5
RXF 393	1.262	2.030	1.974	1.981	1.758	1.333	0.309	93	94	64	9	-76	1.83E-6	1.28E-5	5.00E-5
SN12C	0.507	1.896	1.847	1.700	1.528	0.578	0.060	97	86	74	5	-88	2.21E-6	1.13E-5	3.90E-5
TK-10	0.902	1.970	1.854	1.807	1.990	1.634	0.619	89	85	102	68	-31	1.53E-5	4.85E-5	> 1.00E-4
UO-31	0.736	2.079	1.911	1.878	1.701	1.179	0.046	88	85	72	33	-94	3.65E-6	1.82E-5	4.52E-5
Prostate Cancer															
PC-3	0.528	2.168	2.107	1.993	1.984	0.982	0.381	96	89	89	28	-28	4.31E-6	3.15E-5	> 1.00E-4
DU-145	0.309	1.337	1.412	1.408	1.358	0.434	0.207	107	107	102	12	-33	3.79E-6	1.86E-5	> 1.00E-4
Breast Cancer															
MCF7	0.528	2.843	2.703	2.540	1.917	0.815	0.352	94	87	60	12	-33	1.62E-6	1.87E-5	> 1.00E-4
MDA-MB-231/ATCC	0.695	1.315	1.166	1.041	0.840	0.406	0.073	76	56	23	-42	-90	1.51E-7	2.29E-6	1.50E-5
HS 578T	1.313	2.340	2.244	2.297	2.120	1.429	0.961	91	96	79	11	-27	2.66E-6	1.97E-5	> 1.00E-4
BT-549	1.353	2.734	2.663	2.539	2.552	1.335	0.366	95	86	87	-1	-73	2.62E-6	9.65E-6	4.78E-5
T-47D	0.800	1.996	1.995	1.924	1.835	1.258	0.687	100	94	86	38	-14	5.71E-6	5.37E-5	> 1.00E-4
MDA-MB-468	1.188	2.227	2.171	2.115	2.153	1.392	0.572	95	89	93	20	-52	3.85E-6	1.88E-5	9.42E-5



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 828816 / 1

Experiment ID : 2105NS27

Test Type : 08

Report Date : May 31, 2021


Test Date : May 03, 2021

QNS :










COMI : IA-1149

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Log10 Concentration												GI50	TGI	LC50
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.369	2.506	2.453	2.416	0.653	0.574	0.367	98	96	13	10	.	3.59E-7	8.84E-5	> 1.00E-4
HL-60(TB)	0.436	2.544	2.419	2.482	0.413	0.311	0.241	94	97	-5	-29	-45	2.88E-7	8.88E-7	> 1.00E-4
K-562	0.129	1.499	1.494	1.491	0.243	0.204	0.159	100	99	8	5	2	3.48E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.547	3.006	2.922	2.985	0.958	0.723	0.414	97	99	17	7	-24	3.95E-7	1.69E-5	> 1.00E-4
RPMI-8226	0.660	2.349	2.341	2.309	0.945	0.549	0.384	100	98	17	-17	-42	3.89E-7	3.16E-6	> 1.00E-4
SR	0.210	0.773	0.716	0.749	0.282	0.225	0.155	90	96	13	3	-26	3.56E-7	1.23E-5	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.428	2.731	2.599	2.669	1.176	0.816	0.242	94	97	32	17	-43	5.37E-7	1.90E-5	> 1.00E-4
EKVX	0.635	1.734	1.662	1.661	1.073	1.042	0.605	93	93	40	37	-5	6.45E-7	7.70E-5	> 1.00E-4
HOP-62	0.723	2.622	2.610	2.564	1.382	1.240	0.408	99	97	35	27	-44	5.68E-7	2.42E-5	> 1.00E-4
HOP-92	1.019	1.622	1.572	1.579	1.359	1.123	0.922	92	93	56	17	-10	1.45E-6	4.40E-5	> 1.00E-4
NCI-H226	0.832	2.314	2.262	2.266	1.571	1.300	0.585	96	97	50	32	-30	9.93E-7	3.28E-5	> 1.00E-4
NCI-H23	0.499	1.653	1.670	1.680	0.903	0.669	0.189	101	102	35	15	-62	5.98E-7	1.55E-5	6.94E-5
NCI-H322M	0.823	2.227	2.279	2.256	1.534	1.541	0.744	104	102	51	51	-10	1.04E-5	6.95E-5	> 1.00E-4
NCI-H460	0.310	3.008	3.008	3.111	0.591	0.499	0.305	100	104	10	7	-2	3.77E-7	6.49E-5	> 1.00E-4
NCI-H522	1.376	3.120	3.044	3.061	1.830	1.661	0.853	96	97	26	16	-38	4.57E-7	2.00E-5	> 1.00E-4
Colon Cancer															
COLO 205	0.731	2.882	2.904	2.954	0.838	0.540	0.139	101	103	5	-26	-81	3.49E-7	1.45E-6	2.72E-5
HCC-2998	0.610	2.205	2.078	2.090	0.870	0.646	0.265	92	93	16	2	-57	3.62E-7	1.09E-5	7.73E-5
HCT-116	0.324	3.059	2.931	2.920	0.666	0.259	0.077	95	95	12	-20	-76	3.51E-7	2.42E-6	3.40E-5
HCT-15	0.244	1.819	1.783	1.811	0.378	0.298	0.143	98	99	8	3	-41	3.50E-7	1.19E-5	> 1.00E-4
HT29	0.328	2.308	2.378	2.471	0.618	0.501	0.168	104	108	15	9	-49	4.19E-7	1.42E-5	> 1.00E-4
KM12	1.184	3.393	3.411	3.425	1.721	1.499	1.064	101	101	24	14	-10	4.65E-7	3.83E-5	> 1.00E-4
SW-620	0.252	1.877	1.818	1.847	0.692	0.718	0.255	96	98	27	29	.	4.76E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.930	2.513	2.423	2.413	1.795	1.255	0.575	94	94	55	21	-38	1.37E-6	2.24E-5	> 1.00E-4
SF-295	0.836	2.968	2.854	2.923	1.087	0.938	0.262	95	98	12	5	-69	3.60E-7	1.16E-5	5.56E-5
SF-539	0.697	2.364	2.248	2.277	0.706	0.624	0.067	93	95	1	-11	-90	2.99E-7	1.11E-6	3.12E-5
SNB-19	0.569	2.069	2.021	2.009	0.959	0.841	0.308	97	96	26	18	-46	4.54E-7	1.92E-5	> 1.00E-4
SNB-75	1.737	2.619	2.377	2.397	1.443	1.698	0.754	73	75	-17	-2	-57	1.86E-7	6.53E-7	7.55E-5
U251	0.291	1.826	1.745	1.801	0.639	0.505	0.075	95	98	23	14	-74	4.36E-7	1.44E-5	5.31E-5
Melanoma															
MALME-3M	0.827	2.073	2.011	2.026	1.460	1.230	0.597	95	96	51	32	-28	1.11E-6	3.45E-5	> 1.00E-4
M14	0.430	1.803	1.791	1.772	0.525	0.468	0.072	99	98	7	3	-83	3.35E-7	1.08E-5	4.10E-5
MDA-MB-435	0.617	2.774	2.775	2.690	0.399	0.422	0.259	100	96	-35	-32	-58	2.24E-7	5.38E-7	4.93E-5
SK-MEL-2	1.744	2.987	3.003	3.034	2.668	2.554	1.017	101	104	74	65	-42	1.39E-5	4.07E-5	> 1.00E-4
SK-MEL-28	0.756	2.190	2.214	2.218	1.570	1.393	0.669	102	102	57	44	-12	3.50E-6	6.21E-5	> 1.00E-4
SK-MEL-5	0.736	3.142	3.093	3.139	1.426	0.561	0.070	98	100	29	-24	-91	5.02E-7	3.51E-6	2.47E-5
UACC-257	1.413	3.040	2.985	3.032	2.656	2.486	1.470	97	99	76	66	4	1.80E-5	> 1.00E-4	> 1.00E-4
UACC-62	0.998	2.839	2.813	2.793	1.781	1.570	0.480	99	97	43	31	-52	7.31E-7	2.37E-5	9.47E-5
Ovarian Cancer															
IGROV1	0.382	1.889	1.894	1.862	0.831	0.543	0.274	100	98	30	11	-28	5.06E-7	1.88E-5	> 1.00E-4
OVCAR-3	0.693	1.958	1.939	1.961	1.416	1.116	0.669	98	100	57	33	-3	2.00E-6	8.06E-5	> 1.00E-4
OVCAR-4	1.267	2.692	2.698	2.741	2.230	1.924	1.529	100	103	68	46	18	6.58E-6	> 1.00E-4	> 1.00E-4
OVCAR-5	0.491	1.413	1.339	1.359	0.831	0.752	0.346	92	94	37	28	-30	5.89E-7	3.08E-5	> 1.00E-4
OVCAR-8	0.405	2.356	2.309	2.375	0.816	0.703	0.216	98	101	21	15	-47	4.34E-7	1.76E-5	> 1.00E-4
NCI/ADR-RES	0.600	2.255	2.269	2.310	0.803	0.624	0.436	101	103	12	1	-27	3.85E-7	1.12E-5	> 1.00E-4
SK-OV-3	0.965	2.292	2.334	2.328	1.598	1.569	0.846	103	103	48	46	-12	9.08E-7	6.11E-5	> 1.00E-4
Renal Cancer															
786-O	0.533	2.172	2.362	2.366	1.091	0.746	0.149	112	112	34	13	-72	6.23E-7	1.42E-5	5.51E-5
A498	1.858	2.863	2.694	2.876	1.875	1.552	0.136	83	101	2	-16	-93	3.27E-7	1.23E-6	2.75E-5
ACHN	0.313	1.461	1.425	1.446	0.742	0.503	0.094	97	99	37	17	-70	6.22E-7	1.55E-5	5.88E-5
CAKI-1	0.994	2.786	2.634	2.606	1.688	1.244	0.179	92	90	39	14	-82	6.02E-7	1.40E-5	4.64E-5
RXF 393	0.942	1.623	1.551	1.572	0.925	1.048	0.132	89	92	-2	15	-86	2.82E-7	.	4.42E-5
SN12C	0.844	3.008	2.934	2.892	1.990	1.278	0.443	97	95	53	20	-48	1.23E-6	1.98E-5	> 1.00E-4
TK-10	1.370	2.450	2.330	2.367	2.437	1.973	0.563	89	92	99	56	-59	1.12E-5	3.07E-5	8.36E-5
UO-31	0.709	2.124	1.927	1.955	1.366	1.265	0.449	86	88	46	39	-37	8.20E-7	3.29E-5	> 1.00E-4
Prostate Cancer															
PC-3	0.566	2.119	2.068	2.061	1.025	0.892	0.789	97	96	30	21	14	4.94E-7	> 1.00E-4	> 1.00E-4
DU-145	0.512	2.060	2.133	2.156	0.856	0.584	0.289	105	106	22	5	-44	4.67E-7	1.25E-5	> 1.00E-4
Breast Cancer															
MCF7	0.334	2.254	2.034	2.171	0.628	0.454	0.154	89	96	15	6	-54	3.70E-7	1.27E-5	8.62E-5
MDA-MB-231/ATCC	0.732	1.609	1.650	1.650	0.928	0.703	0.254	105	105	22	-4	-65	4.61E-7	7.03E-6	5.63E-5
HS 578T	1.250	2.503	2.355	2.482	1.576	1.453	1.091	88	98	26	16	-13	4.66E-7	3.63E-5	> 1.00E-4
BT-549	0.986	2.201	2.088	2.213	1.442	0.843	0.364	91	101	37	-15	-63	6.35E-7	5.26E-6	5.37E-5
T-47D	0.977	2.413	2.329	2.385	1.722	1.793	0.976	94	98	52	57	.	1.32E-5	9.96E-5	> 1.00E-4
MDA-MB-468	0.999	2.403	2.246	2.181	1.482	1.250	0.285	89	84	34	18	-72	4.85E-7	1.58E-5	5.74E-5



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 818431 / 1

Experiment ID : 1911NS88

Test Type : 08

Report Date : December 26, 2019


Test Date : November 04, 2019

QNS :










COMI : IA-853

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time	Log10 Concentration										GI50	TGI	LC50	
		Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.560	2.545	2.520	2.492	1.939	0.678	0.550	99	97	69	6	-2	2.02E-6	5.75E-5	> 1.00E-4
HL-60(TB)	0.917	3.300	3.267	3.307	2.765	0.603	0.644	99	100	78	-34	-30	1.76E-6	4.94E-6	> 1.00E-4
K-562	0.194	1.933	1.887	1.828	0.484	0.278	0.334	97	94	17	5	8	3.70E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.642	2.740	2.769	2.797	2.692	0.817	0.909	101	103	98	8	13	3.42E-6	> 1.00E-4	> 1.00E-4
RPMI-8226	0.911	2.406	2.450	2.402	2.021	0.805	0.774	103	100	74	-12	-15	1.91E-6	7.31E-6	> 1.00E-4
SR	0.388	2.214	2.103	2.079	0.769	0.474	0.549	94	93	21	5	9	3.92E-7	> 1.00E-4	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.458	2.623	2.542	2.446	1.738	0.704	1.113	96	92	59	11	30	1.55E-6	> 1.00E-4	> 1.00E-4
EKVX	0.823	2.316	2.237	2.173	1.849	1.319	1.334	95	90	69	33	34	3.36E-6	> 1.00E-4	> 1.00E-4
HOP-62	0.655	2.002	1.888	1.825	1.459	0.768	0.363	91	87	60	8	-45	1.54E-6	1.44E-5	> 1.00E-4
HOP-92	1.228	1.813	1.762	1.707	1.555	1.063	0.954	91	82	56	-13	-22	1.21E-6	6.40E-6	> 1.00E-4
NCI-H226	1.361	2.496	2.437	2.402	2.093	1.058	1.346	95	92	64	-22	-1	1.47E-6	5.54E-6	> 1.00E-4
NCI-H23	0.582	1.843	1.803	1.792	1.556	0.690	0.248	97	96	77	9	-57	2.49E-6	1.35E-5	7.70E-5
NCI-H322M	0.918	2.302	2.174	2.124	1.911	1.266	1.353	91	87	72	25	31	2.93E-6	> 1.00E-4	> 1.00E-4
NCI-H460	0.404	3.243	3.267	3.269	1.759	0.453	0.472	101	101	48	2	2	9.06E-7	> 1.00E-4	> 1.00E-4
NCI-H522	1.037	2.559	2.454	2.448	1.591	0.909	0.651	93	93	36	-12	-37	5.73E-7	5.57E-6	> 1.00E-4
Colon Cancer															
COLO 205	0.437	1.764	1.793	1.791	1.353	0.441	0.425	102	102	69	.	-3	1.89E-6	1.22E-5	> 1.00E-4
HCC-2998	0.648	1.904	1.842	1.807	1.552	0.462	0.586	95	92	72	-29	-10	1.65E-6	5.19E-6	> 1.00E-4
HCT-116	0.285	2.443	2.380	2.371	0.797	0.115	0.243	97	97	24	-60	-15	4.36E-7	1.92E-6	.
HCT-15	0.234	1.806	1.738	1.685	0.708	0.269	0.391	96	92	30	2	10	4.79E-7	> 1.00E-4	> 1.00E-4
HT29	0.226	1.685	1.601	1.691	0.817	0.242	0.303	94	100	41	1	5	6.95E-7	> 1.00E-4	> 1.00E-4
KM12	0.874	3.358	3.358	3.343	1.879	1.247	1.056	100	99	40	15	7	6.89E-7	> 1.00E-4	> 1.00E-4
SW-620	0.358	2.763	2.692	2.629	1.188	0.817	0.878	97	94	35	19	22	5.51E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	1.102	2.838	2.719	2.705	2.287	1.447	0.824	93	92	68	20	-25	2.38E-6	2.76E-5	> 1.00E-4
SF-295	1.271	3.302	3.271	3.261	2.499	1.451	0.677	98	98	60	9	-47	1.60E-6	1.44E-5	> 1.00E-4
SF-539	0.781	2.482	2.439	2.363	1.296	0.395	0.142	97	93	30	-49	-82	4.84E-7	2.40E-6	1.04E-5
SNB-19	0.769	2.525	2.435	2.441	2.113	1.252	0.633	95	95	77	27	-18	3.47E-6	4.05E-5	> 1.00E-4
U251	0.446	2.100	2.045	1.980	1.444	0.576	0.300	97	93	60	8	-33	1.57E-6	1.56E-5	> 1.00E-4
Melanoma															
LOX IMVI	0.616	2.973	2.947	2.899	2.080	0.740	0.936	99	97	62	5	14	1.63E-6	> 1.00E-4	> 1.00E-4
MALME-3M	0.634	1.243	1.208	1.154	0.975	0.612	0.597	94	85	56	-3	-6	1.26E-6	8.74E-6	> 1.00E-4
M14	0.419	1.750	1.717	1.679	1.060	0.377	0.398	98	95	48	-10	-5	9.13E-7	6.73E-6	> 1.00E-4
MDA-MB-435	0.508	2.469	2.439	2.353	0.403	0.268	0.223	98	94	-21	-47	-56	2.42E-7	6.61E-7	2.01E-5
SK-MEL-2	1.085	2.944	2.857	2.873	2.481	1.424	0.480	95	96	75	18	-56	2.76E-6	1.76E-5	8.36E-5
SK-MEL-28	0.703	1.954	1.970	1.931	1.351	1.041	1.005	101	98	52	27	24	1.18E-6	> 1.00E-4	> 1.00E-4
SK-MEL-5	1.246	3.246	3.230	3.273	2.933	0.831	1.569	99	101	84	-33	16	1.96E-6	.	> 1.00E-4
UACC-257	0.795	2.146	2.064	2.044	1.572	1.332	1.544	94	92	58	40	55	.	> 1.00E-4	> 1.00E-4
UACC-62	0.953	2.820	2.766	2.679	1.493	1.184	0.859	97	92	29	12	-10	4.66E-7	3.60E-5	> 1.00E-4
Ovarian Cancer															
IGROV1	0.474	2.077	2.030	1.990	1.186	0.485	0.487	97	95	44	1	1	7.73E-7	> 1.00E-4	> 1.00E-4
OVCAR-3	0.561	1.902	1.931	1.910	0.958	0.209	0.189	102	101	30	-63	-66	5.16E-7	2.09E-6	7.28E-6
OVCAR-4	1.073	2.011	2.037	1.947	1.804	1.361	1.610	103	93	78	31	57	.	> 1.00E-4	> 1.00E-4
OVCAR-5	0.576	1.673	1.627	1.600	1.483	0.858	0.846	96	93	83	26	25	3.75E-6	> 1.00E-4	> 1.00E-4
OVCAR-8	0.563	2.683	2.628	2.613	2.103	0.634	0.755	97	97	73	3	9	2.12E-6	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.593	2.039	2.041	2.033	1.108	0.557	1.061	100	100	36	-6	32	5.96E-7	.	> 1.00E-4
SK-OV-3	0.832	1.847	1.861	1.838	1.552	1.005	0.655	101	99	71	17	-21	2.45E-6	2.78E-5	> 1.00E-4
Renal Cancer															
786-O	0.741	2.644	2.643	2.566	2.181	0.486	0.248	100	96	76	-34	-67	1.71E-6	4.86E-6	3.04E-5
A498	1.676	2.346	2.132	2.167	1.586	1.146	0.742	68	73	-5	-32	-56	1.98E-7	8.54E-7	5.77E-5
ACHN	0.544	2.381	2.392	2.370	1.552	0.693	0.876	101	99	55	8	18	1.27E-6	> 1.00E-4	> 1.00E-4
CAKI-1	1.234	3.091	2.914	2.919	1.861	1.326	1.435	90	91	34	5	11	5.19E-7	> 1.00E-4	> 1.00E-4
RXF 393	0.955	1.882	1.827	1.820	1.306	0.601	0.222	94	93	38	-37	-77	6.03E-7	3.20E-6	2.12E-5
SN12C	0.566	2.192	2.070	2.064	1.863	0.766	0.878	92	92	80	12	19	2.76E-6	> 1.00E-4	> 1.00E-4
TK-10	1.066	1.968	1.818	1.887	1.881	1.062	0.501	83	91	90	.	-53	2.78E-6	9.89E-6	8.77E-5
UO-31	1.009	2.287	2.094	2.023	1.660	0.630	1.532	85	79	51	-38	41	1.02E-6	.	> 1.00E-4
Prostate Cancer															
PC-3	0.532	1.531	1.477	1.430	1.062	0.549	0.644	95	90	53	2	11	1.15E-6	> 1.00E-4	> 1.00E-4
DU-145	0.477	2.094	2.085	2.070	1.894	0.385	0.347	99	99	88	-19	-27	2.25E-6	6.59E-6	> 1.00E-4
Breast Cancer															
MCF7	0.406	2.291	2.148	2.111	0.802	0.654	0.753	92	90	21	13	18	3.82E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.812	2.168	2.157	2.088	1.818	0.860	0.750	99	94	74	4	-8	2.20E-6	2.06E-5	> 1.00E-4
HS 578T	1.691	2.863	2.830	2.785	2.280	1.640	1.576	97	93	50	-3	-7	1.01E-6	8.77E-6	> 1.00E-4
BT-549	1.314	2.393	2.368	2.272	2.136	1.196	1.011	98	89	76	-9	-23	2.03E-6	7.84E-6	> 1.00E-4
T-47D	0.831	1.853	1.814	1.763	1.323	1.273	1.352	96	91	48	43	51	.	> 1.00E-4	> 1.00E-4
MDA-MB-468	0.946	1.569	1.551	1.497	1.030	0.746	0.631	97	88	13	-21	-33	3.25E-7	2.45E-6	> 1.00E-4



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 809813 / 1

Experiment ID : 1812NS41

Test Type : 08

Report Date : January 09, 2019


Test Date : December 10, 2018

QNS :










COMI : MM-158

Stain Reagent : SRB Dual-Pass Related

SSPL : 1AMN



Panel/Cell Line	Time	Log10 Concentration											GI50	TGI	LC50
		Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.392	1.867	1.798	1.709	0.474	0.386	0.431	95	89	6	-2	3	2.95E-7	.	> 1.00E-4
HL-60(TB)	1.027	3.435	3.425	3.444	0.613	0.519	0.323	100	100	-40	-49	-69	2.28E-7	.	1.07E-5
K-562	0.242	2.595	2.484	2.529	0.478	0.315	0.284	95	97	10	3	2	3.48E-7	> 1.00E-4	> 1.00E-4
MOLT-4	0.640	2.714	2.826	2.738	1.472	0.835	0.742	105	101	40	9	5	6.88E-7	> 1.00E-4	> 1.00E-4
RPMI-8226	0.712	2.169	2.170	2.094	0.840	0.561	0.530	100	95	9	-21	-26	3.32E-7	1.96E-6	> 1.00E-4
SR	0.350	1.101	1.119	1.108	0.441	0.361	0.313	102	101	12	1	-11	3.75E-7	1.31E-5	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.277	1.898	1.857	1.795	0.707	0.345	0.229	97	94	26	4	-18	4.47E-7	1.56E-5	> 1.00E-4
EKVX	0.958	2.672	2.527	2.401	1.689	1.254	0.985	92	84	43	17	2	6.66E-7	> 1.00E-4	> 1.00E-4
HOP-62	0.499	1.657	1.662	1.611	0.955	0.449	0.099	100	96	39	-10	-80	6.49E-7	6.24E-6	3.70E-5
HOP-92	1.079	1.802	1.734	1.586	1.620	1.041	0.550	91	70	75	-4	-49	2.07E-6	9.02E-6	> 1.00E-4
NCI-H226	0.874	2.284	2.151	2.116	1.731	0.538	0.453	91	88	61	-39	-48	1.28E-6	4.09E-6	> 1.00E-4
NCI-H23	0.609	2.177	2.086	2.044	1.189	0.749	0.211	94	92	37	9	-65	5.77E-7	1.32E-5	6.21E-5
NCI-H322M	0.577	1.540	1.503	1.449	1.060	0.525	0.448	96	91	50	-9	-22	1.00E-6	7.02E-6	> 1.00E-4
NCI-H460	0.237	2.780	2.855	2.816	0.433	0.157	0.108	103	101	8	-34	-54	3.54E-7	1.53E-6	6.11E-5
NCI-H522	0.367	1.627	1.521	1.449	0.584	0.271	0.156	92	86	17	-26	-58	3.33E-7	2.49E-6	5.72E-5
Colon Cancer															
COLO 205	0.341	1.225	1.222	1.142	0.435	0.235	0.133	100	91	11	-31	-61	3.22E-7	1.80E-6	4.29E-5
HCC-2998	0.419	1.518	1.488	1.432	0.642	0.397	0.316	97	92	20	-5	-25	3.86E-7	6.23E-6	> 1.00E-4
HCT-116	0.145	1.545	1.494	1.471	0.312	0.045	0.025	96	95	12	-69	-83	3.47E-7	1.40E-6	5.78E-6
HCT-15	0.246	1.622	1.601	1.472	0.480	0.263	0.204	98	89	17	1	-17	3.49E-7	1.17E-5	> 1.00E-4
HT29	0.107	1.435	1.466	1.358	0.281	0.051	0.035	102	94	13	-53	-68	3.51E-7	1.58E-6	9.07E-6
KM12	0.529	2.868	2.774	2.734	0.950	0.564	0.380	96	94	18	1	-28	3.80E-7	1.12E-5	> 1.00E-4
SW-620	0.208	1.986	1.960	1.823	0.681	0.431	0.330	98	91	27	13	7	4.32E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.864	2.821	2.769	2.672	1.974	1.201	0.598	97	92	57	17	-31	1.48E-6	2.28E-5	> 1.00E-4
SF-295	0.999	3.047	2.969	2.931	1.271	0.981	0.258	96	94	13	-2	-74	3.52E-7	7.54E-6	4.63E-5
SF-539	0.727	2.129	1.943	1.865	0.524	0.122	0.007	87	81	-28	-83	-99	1.93E-7	5.55E-7	2.51E-6
SNB-19	0.503	1.799	1.741	1.724	0.897	0.619	0.275	95	94	30	9	-45	4.92E-7	1.46E-5	> 1.00E-4
SNB-75	1.122	1.831	1.647	1.652	1.191	0.734	0.274	74	75	10	-35	-76	2.40E-7	1.66E-6	2.37E-5
U251	0.297	1.705	1.653	1.523	0.661	0.418	0.190	96	87	26	9	-36	4.03E-7	1.56E-5	> 1.00E-4
Melanoma															
LOX IMVI	0.317	2.430	2.389	2.287	0.959	0.252	0.106	98	93	30	-21	-67	4.87E-7	3.94E-6	4.36E-5
MALME-3M	0.614	1.454	1.382	1.307	1.005	0.563	0.473	91	82	46	-8	-23	7.99E-7	7.05E-6	> 1.00E-4
M14	0.454	2.114	2.000	2.016	0.684	0.455	0.245	93	94	14	.	-46	3.54E-7	1.00E-5	> 1.00E-4
MDA-MB-435	0.574	2.734	2.662	2.581	0.527	0.432	0.249	97	93	-8	-25	-57	2.66E-7	8.30E-7	6.17E-5
SK-MEL-2	0.575	2.074	2.023	1.960	1.325	0.603	0.102	97	92	50	2	-82	1.00E-6	1.05E-5	4.13E-5
SK-MEL-28	0.596	1.836	1.791	1.702	1.131	0.570	0.410	96	89	43	-4	-31	7.09E-7	8.06E-6	> 1.00E-4
SK-MEL-5	0.793	3.059	2.921	2.834	0.961	0.196	0.059	94	90	7	-75	-93	3.05E-7	1.23E-6	4.94E-6
UACC-257	0.821	2.258	2.189	2.156	1.804	1.211	0.996	95	93	68	27	12	2.79E-6	> 1.00E-4	> 1.00E-4
UACC-62	1.043	3.018	2.935	2.857	1.726	0.991	0.356	96	92	35	-5	-66	5.38E-7	7.48E-6	5.49E-5
Ovarian Cancer															
IGROV1	0.197	0.795	0.775	0.758	0.366	0.121	0.076	97	94	28	-39	-61	4.66E-7	2.63E-6	3.12E-5
OVCAR-3	0.508	1.847	1.840	1.831	0.389	0.253	0.232	99	99	-24	-50	-54	2.50E-7	6.42E-7	9.83E-6
OVCAR-4	0.706	1.720	1.686	1.549	1.225	0.832	0.740	97	83	51	12	3	1.07E-6	> 1.00E-4	> 1.00E-4
OVCAR-5	0.443	1.207	1.194	1.133	0.625	0.309	0.268	98	90	24	-30	-40	4.04E-7	2.75E-6	> 1.00E-4
OVCAR-8	0.411	2.297	2.278	2.276	0.984	0.554	0.327	99	99	30	8	-21	5.17E-7	1.86E-5	> 1.00E-4
NCI/ADR-RES	0.567	1.940	1.922	1.863	0.783	0.485	0.336	99	94	16	-14	-41	3.66E-7	3.32E-6	> 1.00E-4
SK-OV-3	0.674	1.569	1.604	1.502	0.983	0.601	0.210	104	93	35	-11	-69	5.42E-7	5.77E-6	4.73E-5
Renal Cancer															
786-0	0.501	2.294	2.156	2.033	1.343	0.698	0.161	92	85	47	11	-68	8.33E-7	1.38E-5	5.92E-5
A498	1.381	2.073	1.939	1.757	1.170	0.851	0.468	81	54	-15	-38	-66	1.15E-7	6.03E-7	2.62E-5
ACHN	0.340	1.332	1.338	1.293	0.748	0.235	0.112	101	96	41	-31	-67	6.90E-7	3.72E-6	3.34E-5
CAKI-1	0.571	2.095	1.950	1.831	1.205	0.244	0.012	90	83	42	-57	-98	6.23E-7	2.63E-6	8.44E-6
RXF 393	0.790	1.312	1.309	1.283	0.822	0.613	0.107	99	94	6	-22	-86	3.18E-7	1.63E-6	2.70E-5
SN12C	0.417	1.561	1.502	1.490	0.780	0.293	0.150	95	94	32	-30	-64	5.08E-7	3.28E-6	3.89E-5
TK-10	0.496	1.851	1.719	1.655	1.270	0.662	0.087	90	86	57	12	-82	1.44E-6	1.35E-5	4.54E-5
UO-31	0.509	1.654	1.506	1.564	1.075	0.572	0.235	87	92	49	5	-54	9.70E-7	1.24E-5	8.59E-5
Prostate Cancer															
PC-3	0.392	1.679	1.586	1.551	0.654	0.354	0.278	93	90	20	-10	-29	3.75E-7	4.75E-6	> 1.00E-4
DU-145	0.369	1.959	1.972	1.879	0.733	0.368	0.256	101	95	23	.	-31	4.20E-7	9.73E-6	> 1.00E-4
Breast Cancer															
MCF7	0.430	2.273	2.102	2.089	0.768	0.526	0.419	91	90	18	5	-3	3.62E-7	4.58E-5	> 1.00E-4
MDA-MB-231/ATCC	0.551	1.303	1.291	1.227	0.687	0.390	0.225	98	90	18	-29	-59	3.59E-7	2.41E-6	4.93E-5
HS 578T	1.026	2.200	2.126	2.044	1.117	0.899	0.810	94	87	8	-12	-21	2.91E-7	2.43E-6	> 1.00E-4
BT-549	1.444	2.600	2.548	2.676	2.193	1.093	0.642	96	107	65	-24	-56	1.47E-6	5.34E-6	6.63E-5
T-47D	0.587	1.273	1.250	1.172	0.882	0.507	0.446	97	85	43	-14	-24	6.80E-7	5.73E-6	> 1.00E-4
MDA-MB-468	0.838	1.774	1.715	1.735	0.801	0.572	0.277	94	96	-4	-32	-67	2.87E-7	9.04E-7	3.29E-5



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 809967 / 1

Experiment ID : 1901NS52

Test Type : 08

Report Date : February 06, 2019


Test Date : January 14, 2019

QNS :










COMI : IA-736

Stain Reagent : SRB Dual-Pass Related


SSPL : 1AMN




Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration						Percent Growth					GI50	TGI	LC50
			-8.3	-7.3	-6.3	-5.3	-4.3	-8.3	-7.3	-6.3	-5.3	-4.3				
Leukemia																
CCRF-CEM	0.437	2.544	2.509	2.530	2.547	1.037	0.702	98	99	100	28	13	2.50E-6	> 5.00E-5	> 5.00E-5	
HL-60(TB)	0.908	3.072	3.164	3.015	3.099	1.227	0.900	104	97	101	15	.	1.96E-6	4.39E-5	> 5.00E-5	
K-562	0.163	2.000	2.075	2.038	2.132	0.316	0.406	104	102	107	8	13	1.89E-6	> 5.00E-5	> 5.00E-5	
MOLT-4	0.709	2.989	3.011	3.014	3.082	1.710	1.186	101	101	104	44	21	3.96E-6	> 5.00E-5	> 5.00E-5	
RPMI-8226	0.901	2.823	2.783	2.710	2.797	1.483	1.364	98	94	99	30	24	2.57E-6	> 5.00E-5	> 5.00E-5	
SR	0.448	1.922	1.835	1.831	1.848	0.620	0.738	94	94	95	12	20	1.73E-6	> 5.00E-5	> 5.00E-5	
Non-Small Cell Lung Cancer																
A549/ATCC	0.420	2.170	2.018	2.051	2.065	0.426	0.912	91	93	94	.	28	1.47E-6	> 5.00E-5	> 5.00E-5	
EKVX	0.753	1.676	1.608	1.524	1.541	1.109	1.200	93	84	85	39	48	2.84E-6	> 5.00E-5	> 5.00E-5	
HOP-62	0.758	2.488	2.423	2.426	2.398	0.945	0.791	96	96	95	11	2	1.71E-6	> 5.00E-5	> 5.00E-5	
HOP-92	1.219	2.030	1.896	1.852	1.845	1.541	1.685	83	78	77	40	57	.	> 5.00E-5	> 5.00E-5	
NCI-H226	1.223	2.926	2.868	2.802	2.840	1.525	2.101	97	93	95	18	52	.	> 5.00E-5	> 5.00E-5	
NCI-H23	0.599	2.311	2.221	2.187	2.277	0.934	0.738	95	93	98	20	8	2.05E-6	> 5.00E-5	> 5.00E-5	
NCI-H322M	0.663	1.950	1.865	1.795	1.712	0.908	1.143	93	88	82	19	37	1.60E-6	> 5.00E-5	> 5.00E-5	
NCI-H460	0.429	2.901	2.909	2.924	2.902	0.211	0.366	100	101	100	-51	-15	1.07E-6	2.30E-6	.	
NCI-H522	0.888	2.488	2.343	2.226	2.282	1.002	0.982	91	84	87	7	6	1.45E-6	> 5.00E-5	> 5.00E-5	
Colon Cancer																
COLO 205	0.484	2.046	1.934	1.996	2.031	0.843	0.470	93	97	99	23	-3	2.21E-6	3.83E-5	> 5.00E-5	
HCC-2998	0.731	2.844	2.803	2.755	2.767	1.860	0.770	98	96	96	53	2	5.82E-6	> 5.00E-5	> 5.00E-5	
HCT-116	0.236	2.642	2.536	2.564	2.581	0.226	0.453	96	97	97	-4	9	1.46E-6	.	> 5.00E-5	
HCT-15	0.249	1.761	1.745	1.645	1.651	0.388	0.391	99	92	93	9	9	1.62E-6	> 5.00E-5	> 5.00E-5	
HT29	0.259	1.891	1.825	1.808	1.750	0.331	0.391	96	95	91	4	8	1.50E-6	> 5.00E-5	> 5.00E-5	
KM12	0.581	2.815	2.755	2.730	2.668	0.584	0.682	97	96	93	.	4	1.46E-6	> 5.00E-5	> 5.00E-5	
SW-620	0.450	1.950	1.891	1.894	1.870	0.391	0.810	96	96	95	-13	24	1.30E-6	.	> 5.00E-5	
CNS Cancer																
SF-268	0.949	2.354	2.262	2.191	2.123	0.908	1.235	93	88	84	-4	20	1.20E-6	.	> 5.00E-5	
SF-295	0.933	3.024	2.905	2.841	2.863	0.951	0.978	94	91	92	1	2	1.45E-6	> 5.00E-5	> 5.00E-5	
SF-539	0.585	2.050	1.961	1.824	1.889	0.072	0.151	94	85	89	-88	-74	8.31E-7	1.59E-6	3.06E-6	
SNB-19	0.780	2.513	2.400	2.357	2.356	1.449	1.260	93	91	91	39	28	3.03E-6	> 5.00E-5	> 5.00E-5	
SNB-75	1.190	1.951	1.770	1.740	1.715	0.774	0.751	76	72	69	-35	-37	7.62E-7	2.31E-6	> 5.00E-5	
U251	0.361	1.773	1.750	1.699	1.756	0.328	0.376	98	95	99	-9	1	1.42E-6	.	> 5.00E-5	
Melanoma																
LOX IMVI	0.445	3.113	3.079	3.031	3.040	0.447	0.882	99	97	97	.	16	1.53E-6	> 5.00E-5	> 5.00E-5	
MALME-3M	0.876	1.983	1.841	1.742	1.751	0.864	1.132	87	78	79	-1	23	1.15E-6	.	> 5.00E-5	
M14	0.547	2.583	2.504	2.503	2.533	1.341	0.878	96	96	98	39	16	3.24E-6	> 5.00E-5	> 5.00E-5	
MDA-MB-435	0.766	2.935	2.898	2.810	2.753	0.364	0.237	98	94	92	-52	-69	9.72E-7	2.16E-6	4.81E-6	
SK-MEL-2	1.055	2.629	2.476	2.483	2.509	1.661	1.176	90	91	92	38	8	3.06E-6	> 5.00E-5	> 5.00E-5	
SK-MEL-28	0.812	2.534	2.552	2.513	2.388	1.237	1.456	101	99	92	25	37	2.09E-6	> 5.00E-5	> 5.00E-5	
SK-MEL-5	0.982	3.282	3.266	3.219	3.247	1.923	1.180	99	97	98	41	9	3.48E-6	> 5.00E-5	> 5.00E-5	
UACC-257	1.152	2.518	2.437	2.393	2.372	1.693	1.804	94	91	89	40	48	3.09E-6	> 5.00E-5	> 5.00E-5	
UACC-62	1.153	3.017	2.970	2.949	2.847	1.846	1.866	97	96	91	37	38	2.89E-6	> 5.00E-5	> 5.00E-5	
Ovarian Cancer																
IGROV1	0.550	2.229	2.195	2.067	2.045	0.765	0.803	98	90	89	13	15	1.63E-6	> 5.00E-5	> 5.00E-5	
OVCAR-3	0.634	2.111	2.087	2.004	2.015	0.263	0.294	98	93	93	-59	-54	9.66E-7	2.06E-6	4.39E-6	
OVCAR-4	0.694	1.519	1.471	1.383	1.442	0.624	1.131	94	84	91	-10	53	.	.	> 5.00E-5	
OVCAR-5	0.617	1.711	1.655	1.606	1.535	0.925	0.795	95	90	84	28	16	2.03E-6	> 5.00E-5	> 5.00E-5	
OVCAR-8	0.474	2.090	2.051	2.016	1.990	0.481	0.714	98	95	94	.	15	1.47E-6	> 5.00E-5	> 5.00E-5	
NCI/ADR-RES	0.543	2.042	1.973	1.978	1.920	0.536	0.648	95	96	92	-1	7	1.41E-6	.	> 5.00E-5	
SK-OV-3	0.914	2.158	2.028	2.039	2.027	1.352	1.203	89	90	89	35	23	2.67E-6	> 5.00E-5	> 5.00E-5	
Renal Cancer																
786-0	0.836	3.052	2.970	2.985	2.981	0.926	1.102	96	97	97	4	12	1.60E-6	> 5.00E-5	> 5.00E-5	
A498	2.033	2.603	2.396	2.328	2.399	1.410	1.250	64	52	64	-31	-39	7.05E-7	2.37E-6	> 5.00E-5	
ACHN	0.450	1.953	1.927	1.892	1.858	0.490	0.643	98	96	94	3	13	1.51E-6	> 5.00E-5	> 5.00E-5	
CAKI-1	0.880	2.528	2.400	2.276	2.283	1.252	1.247	92	85	85	23	22	1.82E-6	> 5.00E-5	> 5.00E-5	
RXF 393	0.904	1.614	1.555	1.561	1.518	0.818	0.813	92	92	86	-10	-10	1.20E-6	3.98E-6	> 5.00E-5	
SN12C	0.660	2.809	2.703	2.667	2.621	1.422	1.093	95	93	91	35	20	2.74E-6	> 5.00E-5	> 5.00E-5	
TK-10	0.576	2.029	1.972	1.960	1.932	0.757	0.968	96	95	93	12	27	1.72E-6	> 5.00E-5	> 5.00E-5	
UO-31	1.055	2.394	2.219	2.158	2.043	1.347	1.512	87	82	74	22	34	1.43E-6	> 5.00E-5	> 5.00E-5	
Prostate Cancer																
PC-3	0.610	2.645	2.633	2.583	2.538	1.229	1.209	99	97	95	30	29	2.48E-6	> 5.00E-5	> 5.00E-5	
DU-145	0.500	2.023	2.074	1.993	1.975	0.960	0.747	103	98	97	30	16	2.52E-6	> 5.00E-5	> 5.00E-5	
Breast Cancer																
MCF7	0.494	2.551	2.376	2.318	2.368	0.802	0.990	91	89	91	15	24	1.73E-6	> 5.00E-5	> 5.00E-5	
MDA-MB-231/ATCC	0.676	1.604	1.635	1.517	1.563	0.793	0.495	103	91	96	13	-27	1.77E-6	1.04E-5	> 5.00E-5	
HS 578T	1.244	2.181	2.091	2.067	2.063	1.000	1.113	90	88	87	-20	-11	1.12E-6	3.28E-6	> 5.00E-5	
BT-549	1.117	2.371	2.250	2.282	2.270	1.784	1.402	90	93	92	53	23	6.34E-6	> 5.00E-5	> 5.00E-5	
T-47D	0.804	2.017	1.991	1.918	1.886	0.974	1.378	98	92	89	14	47	1.66E-6	> 5.00E-5	> 5.00E-5	
MDA-MB-468	0.998	1.718	1.670	1.607	1.652	1.000	1.020	93	85	91	.	3	1.41E-6	> 5.00E-5	> 5.00E-5	




/KANI IA754.1




4c




/KANI IA754.1




4c




/KANI IA624.1




4d




/KANI IA624.2




4d




/KANI IA842.1




4e




/KANI IA842.1




4e




/KANI KN164.1




/KANI KN164.1




4f




/KANI IA1102.1




4g





/KANI IA1102.1




4g




/KANI VDB48.1





/KANI VDB48.1 DMSO-d6 13C 18mg 512scans




4h




/KANI IA628.1




/KANI IA628.2




4i





/KANI MM189.1




4j




/KANI IA634.2





/KANI IA630.1



4k



/KANI IA630.1




/KANI IA856.1

7.657
7.631
7.605
7.541
7.517
7.249
7.222
7.129
7.104
7.079


3.459
3.389
3.365

2.498


0.986
0.964
0.935




4I





/KANI IA856.1





4I




/KANI IA1153.1




/KANI IA1118.1




/KANI IA843.2




4n





/KANI IA843.2





4n





/KANI IA1657.1




/KANI IA1657.1





/KANI MM190.1




4p



/KANI MM190.1



/KANI IA852.1




7.675
7.649
7.623
7.542
7.517
7.179
7.153
7.140
7.114
7.089

3.662
3.639
3.615
3.367



2.500

1.610
1.588
1.565
1.286
1.276
1.227



0.852
0.831
0.808





/KANI IA852.1





/KANI IA737.1





/KANI IA737.1





/KANI IA739.2





/KANI IA739.2





/KANI IA727.2




/KANI IA727.2




/KANI MM188.1



/KANI MM188.1



/KANI IA627.1




8.85
8.82

7.47
7.44
7.41
7.30
7.17
7.15
7.12
7.11
7.10
6.95
6.94



4.99
4.97
4.95
4.94
4.93
4.92

3.77
3.74
3.72
3.40
3.39
3.38
3.36
3.35
3.33
3.31
3.21
3.19
3.16
3.14
3.12
3.09
2.99
2.90



1.67
1.67
1.65
1.62
1.61
1.60
1.58
1.18
1.16
1.14
1.13
1.12
1.02
0.97
0.91
0.89
0.87





/KANI IA627.1





/KANI IA847.1





/KANI IA847.1





/KANI IA755.1




/KANI IA755.1




/KANI MM162.1





/KANI MM162.1





166.881
160.361
157.691
150.001
143.389
131.717
129.778
127.525
124.502
122.297
119.385
109.253
64.329
63.129
40.333
38.954
38.054
37.409
36.321
35.222
38.944
38.672
35.103
34.427
29.062
19.470
13.504
13.415
12.761





/KANI IA657.1





/KANI IA657.1




/KANI MM203.1



/KANI MM203.1



/KANI IA658.1



8.868
8.842


7.495
7.470
7.444
7.193
7.175
7.148
7.122
6.968
6.961

5.006
4.987
4.963
4.956
4.945
4.939



3.826
3.819
3.810
3.779
3.415
3.392
3.370
3.335
3.199
3.175
3.154
3.130
3.110

2.554
2.515



1.605
1.585
1.562
1.540
1.516
1.492
1.474
1.195
1.171
1.147
1.006
0.984
0.949
0.928
0.901





/KANI IA658.1





/KANI IA732.1





/KANI IA732.1




/KANI IA1152.1



/KANI IA1152.1



/KANI IA846.1



8.895
8.869


7.462
7.436
7.410
7.205
7.178
7.148
7.122
7.097
6.912

4.987
4.967
4.932
4.918
4.912
4.728
4.701
4.673
4.646


3.430
3.405
3.381
3.359
3.335
3.311
3.221
3.204
3.181
3.159
3.145
3.135
3.122
3.099
3.075
2.936

2.050
2.025
1.908
1.661


1.188
1.165
1.141
1.004
0.980
0.957




/KANI IA846.1




166.809
160.380
157.690
150.077
142.943
131.606
129.619
127.628
124.788
122.130
119.604
109.926
64.344
63.123
52.607
40.333
40.060
39.777
39.502
39.224
38.947
38.669
35.108
34.424
27.711
24.567
13.412
12.779





/KANI MM147.1



/KANI MM147.1





/KANI IA728.1





/KANI IA728.2

166.864 160.360 157.693 150.002 143.384 131.715 129.788 127.527 124.491 122.295 119.378 109.237 64.320 63.122 40.336 40.061 39.784 39.641 39.503 39.288 38.951 38.679 35.106 34.423 30.773 26.897 25.826 21.928 13.799 13.421 12.762



/KANI IA883.1



/KANI IA883.1

166.834

160.323

157.660

149.965

143.357

131.675

129.754

127.498

124.466

122.259

119.352

109.197

64.302

63.107

40.058

39.780

39.618

39.502

39.221

38.937

38.664

35.075

34.357

31.203

28.910



26.117

21.919



13.806

13.387





12.733





/KANI IA742.1



/KANI IA742.1





/KANI IA745.1





/KANI IA745.1



166.843
160.336
157.704
149.988
143.350
131.658
129.772
127.530
124.460
122.267
119.369
109.174
64.319
63.123
40.345
40.058
39.777
39.624
39.507
39.224
38.949
38.672
35.105
34.425
31.192
28.822
28.564
26.904
26.160
22.042
13.850
13.418
12.754





/KANI IA748.1



/KANI IA748.1



/KANI IA875.1



/KANI GOA13.1

168.527

164.161

157.958

142.481

136.722

131.598

130.894

127.174

123.079

121.666

120.245

110.170

63.517

61.608

40.316

40.071

39.788

39.511

39.237

38.934



38.669

37.952



34.860

13.014



12.713





/KANI IA626.1





/KANI IA626.1





/KANI IA756.1





/KANI IA756.1





/KANI MM164.1




/KANI MM164.1





/KANI IA643.1





/KANI IA643.1




/KANI MM199.1





/KANI MM195.1




/KANI IA662.1




/KANI IA662.1





/KANI IA866.1





/KANI IA866.1





/KANI IA1149.1





/KANI IA1149.1




/KANI IA853.1




/KANI IA853.1





/KANI MM158.1





/KANI MM158.1




/KANI IA736.1



/KANI IA736.1





/KANI IA888.1





/KANI IA888.1

167.022
164.077
158.038
142.807
136.598
132.999
130.914
127.188
122.192
122.079
119.700
109.151
63.642
61.743
40.097
39.931
39.783
39.702
39.597
39.430
39.263
39.095
38.060
34.961
31.198
28.318
27.102
26.242
22.035
13.931
13.130
12.820





/KANI IA744.3





/KANI IA744.1

166.907
163.943
157.948
142.690
136.516
132.825
130.787
127.084
122.059
119.590
108.999
63.569
61.718
40.052
39.786
39.605
39.503
39.227
38.946
38.007
34.614
31.571
28.502
26.982
26.180
21.977
13.828
13.055
12.715





/KANI IA746.2





/KANI IA746.1

166.928
163.967
157.943
142.694
136.489
132.874
130.798
127.082
122.078
119.600
109.042
63.561
61.674
40.314
40.042
39.760
39.507
39.230
38.959
38.688
37.972
34.856
34.581
28.748
28.469
26.936
26.119
21.994
13.827
13.036
12.707





/KANI IA749.1




/KANI IA749.1


166.961
163.966
158.018
142.758
136.555
132.807
130.777
127.173
122.064
119.693
108.946
63.722
61.956
39.681
39.453
38.137
34.981
31.270
28.882
28.604
27.036
26.227
22.067
13.853
13.590
12.790



/KANI IA1000.1



/KANI IA1000.1



166.820

164.071

158.421

142.258

136.726

136.642

132.673

130.839

127.285

122.489

122.462

121.936

119.930

109.978

63.983

62.137

62.102

44.870

44.210

41.863

40.953

39.835

39.748

39.580

39.414

39.247

39.079


20.895

20.517



19.269

11.157



11.138




/KANI IA1001.1





/KANI IA1001.1





/KANI IA1002.1





/KANI IA1002.1





/KANI VDB33.1




/KANI IA615.1




/KANI IA921.1



/KANI IA910.1



8



Space groups, unit cell parameters and characteristics of the investigated verification phases of compounds **1f-h**, **1j**, **1k**, **1n**, **1p**, **1r**, **1u-w** and **5b**, **5e**, **5f**, **5h**, **5k**, **5p**, **5r**, **5x-z**

Compd	Sp. gr, Z	a, (Å)	b, (Å)	c, (Å)	α , (°)	β , (°)	γ , (°)	V(Å ³)	Number of reflections	Snyder's FOM
1f	P 1 2/m 1, Z=4	16.189(1)	18.158(1)	7.1760(6)	90	94.283(1)	90	2103.50	119	51.9484
1g	P 21 21 2	20.651(1)	15.0646(6)	6.8950(3)	90	90	90	2145.02	107	107.9686
1h	P 1 21/a 1, Z=4	23.371(3)	15.236(2)	6.9576(9)	90	114.305(2)	90	2257.78	120	33.9820
1j	P-1, Z=2	13.081(8)	8.878(8)	8.749(9)	93.472(2)	95.911(1)	85.963(2)	1006.51	134	45.6973
1k	P 1 21/m 1, Z=4	15.9439(9)	19.658(1)	7.0715(4)	90	93.6627(9)	90	2211.83	150	76.5357
1n	P 1 21/m 1, Z=8	22.577(2)	13.9387(9)	15.041(1)	90	93.560(1)	90	4724.05	136	20.1530
1p	P 1 21/c 1, Z=4	16.784(2)	10.4079(9)	13.880(1)	90	93.031(2)	90	2421.33	135	38.9140
1r	P 1 21/m 1, Z=4	23.372(1)	7.1321(5)	14.515(1)	90	92.580(1)	90	2417.15	172	56.5066
1u	P-1, Z=2	17.916(4)	13.086(2)	6.891(7)	86.708(2)	94.302(2)	125.909(2)	1304.56	111	36.6937
1v	P-1, Z=2	13.338(2)	15.911(2)	7.207(8)	101.49(2)	97.339(2)	76.116(2)	1450.08	127	32.9127
1w	P-1, Z=2	13.336(9)	15.940(8)	6.862(5)	95.194(3)	95.753(1)	76.1964(8)	1406.12	142	64.8999
5b	P 21 21 21, Z=4	15.3070(6)	22.175(1)	6.9402(4)	90	90	90	2355.67	165	92.6832
5e	P-1, Z=2	15.179(2)	11.893(1)	4.989(6)	93.379(4)	98.268(2)	96.171(2)	883.59	132	62.2606
5f	P 1 21/m 1, Z=4	4.7283(4)	16.034(2)	27.915(2)	90	91.885(2)	90	2115.14	50	24.7087
5h	P-1, Z=2	14.408(2)	14.763(2)	4.918(7)	90.4193(9)	91.941(2)	100.442(2)	1027.94	76	27.4810
5k	P 1 21/m 1, Z=4	24.615(2)	4.9126(5)	18.353(1)	90	90.686(1)	90	2219.12	121	43.9750
5p	P 1 21/m 1, Z=4	31.236(2)	5.1185(4)	14.3963(8)	90	91.6540(9)	90	2300.74	137	54.7400
5r	P 42/m n m, Z=4	23.0687(8)	23.0687(8)	5.0189(4)	90	90	90	2670.89	89	91.7042
5x	P 1 21/m 1, Z=4	4.7314(3)	27.875(2)	16.848(1)	90	91.381(1)	90	2221.40	87	58.3629
5y	P 1 2/m 1, Z=8	19.288(1)	26.472(1)	10.3345(6)	90	97.4937(9)	90	5231.72	131	24.1674
5z	Pbm m, Z=4	19.426(1)	26.664(1)	4.9117(4)	90	90	90	2544.12	110	58.4252

Powder diffraction pattern

